

Date of Preparation: 07/25/2019

CURRICULUM VITAE

SUBHASH C. CHAUHAN, PhD

Professor and Chairman (Tenured)

Department of Microbiology and Immunology

Director, Institute of Cancer Immunotherapy

School of Medicine

University of Texas Rio Grande Valley (UTRGV)

Edinburg, Texas, 78504

Email: subhash.chauhan@utrgv.edu

Phone: 901-448-2175



EDUCATION:

Ph.D. (December, 1997) Major Reproductive Endocrinology

Title: “**Studies on cytological and molecular mechanism of an anti-implantation action of a triphenylethylene antiestrogen Centchroman in Rat**” from Central Drug Research Institute (CDRI), Lucknow 226 001, India.

M.S. (July, 1990) Zoology, with Honors from H.N.B. Garhwal University, Srinagar, Garhwal, India.

B.S. (July, 1987) Zoology, Botany and Chemistry from H.N.B. Garhwal University, Srinagar, Garhwal, India.

HONORS/AWARDS:

1. Qualified National Eligibility Test (NET) for Lecturer ship conducted by CSIR-UGC, New Delhi, India 1990.
2. Qualified NET for Junior Research Fellowship & Lecturer ship conducted by CSIR-UGC, New Delhi, India 1991.
3. Research Associate awarded by Indian Council of Medical Research (ICMR), 1997.
4. Research Associate awarded by Council for Scientific & Industrial Research (CSIR), 1998.
5. The Corner Stone Club award in System Service Excellence (2010)
6. Outstanding Mentored Academic Inductee 2013-2014 (UTHSC)
7. Outstanding Achievement Award (Society of America Asian Scientist in Cancer Research 2018, SAASCR, USA)
8. Shri R. J. Kinarivala Cancer Research Award 2018-2019 (The Gujarat Cancer & Research Institute and The Gujarat Cancer Society)
9. Mahatma Gandhi Samman, NRI Welfare Society of India, 2018
10. Hind Rattan Award, NRI Welfare Society of India, 2018-2019

SOCIETY MEMBERSHIPS:

1. American Association for Cancer Research (AACR)
2. American Association for Advancement of Science (AAAS)
3. Perinatal Research Society (PRS)
4. South Dakota Academy of Science (SDAS)

UNIVERSITY (AND COLLEGE) APPOINTMENTS:

06/1/19 to present: **Professor and Chairman (Tenured)**
Department of Microbiology and Immunology
Director, Institute of Cancer Immunotherapy
School of Medicine
University of Texas Rio Grande Valley (UTRGV)
Edinburg, Texas, 78504

PRACTICE/PROFESSIONAL EXPERIENCE:

06/17/13-05/31/19: Professor
Department of Pharmaceutical sciences
College of Pharmacy and Cancer Research Center
University of Tennessee Health Science Center (UTHSC)
Memphis, Tennessee, 38163

06/01/17-05/31/19: Director
Institute of Biomarkers and Molecular Therapeutics
University of Tennessee Health Science Center (UTHSC)
Memphis, Tennessee, 38163

8/01/10-06/17/13: Scientist, Cancer Biology Research Center
Sanford Research/USD
Associate Professor
Department of OB/GYN and Basic Biomedical Science Division
Sanford School of Medicine (SSM)
The University of South Dakota
Sioux Falls, South Dakota, 57103

12/01/05-07/30/10: Associate Scientist, Cancer Biology Research Center
Sanford Research/USD
Assistant Professor,
Department of OB/GYN and Basic Biomedical Science Division
Sanford School of Medicine (SSM)
The University of South Dakota
Sioux Falls, South Dakota, 57103

06/01/2004- 12/01/05: Research Associate
Department of Biochemistry and Molecular Biology,

University of Nebraska Medical Center (UNMC)
Omaha, Nebraska, 68191

06/01/2001- 05/30/2004: Post Doctoral Fellow
Department of Biochemistry and Molecular Biology,
University of Nebraska Medical Center (UNMC)
Omaha, Nebraska, 68191

06/02/1999 – 05/30/2001: Post Doctoral Research Associate
Department of OB /GYN
Medical College of Ohio (MCO)
Toledo, Ohio USA

1998 - 1999: **Scientific Officer (Electron Microscopy)**,
Department of Pathology, Sanjay Gandhi Post Graduate Institute of Medical Sciences
(SGPGIMS), Lucknow, India.

1997 -1998: Research Associate, Department of Endocrinology, SGPGIMS, Lucknow, India.

1995 –1997: Senior Research Fellow (SRF), Division of Endocrinology CDRI, Lucknow, India.

1992 –1995: Junior Research Fellow (JRF), Division of Endocrinology CDRI, Lucknow, India.

TEACHING EXPERIENCE:

DELIVERY AND BIOCOMPATIBILITY OF PROTEIN AND NUCLEIC ACID DRUGS
course (PHAC 911; 3 Credit Hrs) was directed and taught to the graduate students (#3
regular one temporary).

Involve in teaching of Foundation of Pharmacy Course (PHCY 115)

One 2 hrs lecture was given to P3 nuclear medicine students (college of pharmacy) (# 8).

Additionally, five graduate student is being directed for PhD degree.

Serving as a graduate student committee member for 7 students.

I am also involved in mentoring a junior faculty member and four postdocs. One other PhD
student is receiving input for his PhD as a committee member.

VISITING PROFESSORSHIPS AND INVITED LECTURES:

1. **Radioimmunotherapy of Cancer with Engineered Single Chain Antibodies:** The
University of North Texas Health Science Center, Fort Worth, Texas (March 2005).

2. **Current advances in ovarian cancer diagnosis and treatment:** (OB/GYN Grand round seminar schedule on February 13 2009) at USD, Sioux Falls, SD.
3. **Radioimmunotherapy of Cancer with Engineered Single Chain Antibodies:** South Dakota Health Research Foundation (SDHRF), Sioux Falls, South Dakota (September, 2005).
4. **Multi-targeted Radioimmunotherapy for Ovarian Cancer:** Sioux Valley Hospital Tumor Conference, Sioux Falls, South Dakota (April, 2006).
5. **Antibody Guided Cancer Diagnosis and Treatment:** South Dakota State University (SDSU), Brookings, South Dakota (March 23, 2007).
6. **Cell Signaling Through Mucins in Cancer:** South Dakota Academy of Science Annual Conference, Brookings, South Dakota (April 13, 2007)
7. **Role of MUC13 Mucin in Cancer:** Sanford Health, Tumor Conference, Sioux Falls, SD, (May 2007)
8. **Magic Bullets for Cancer Treatment and Diagnosis:** Invited seminar at Industrial Toxicology Research Center (ITRC) Lucknow, India (December 2007)
9. **Mucins in Cancer Progression:** The National Academy of Science India invited seminar at Central Drug Research Institute Lucknow, India (January 2008)
10. **Invited for talk and chair session for First World Congress on Cancer 2009(WCC-2009) January 12-14, 2009, Kottayam, Kerala, India (declined because of time conflict)**
11. **Role of MUC13 mucin in pancreatic cancer diagnosis and pathogenesis** (Invited talk for 3rd International meeting Symposium on Translational Research: Cancer Cell Signaling and Therapy to be held from December 18 through 21, 2009 in Bhubneshwar (Orissa), India. *Organizing committee provided full funding for the hotel accommodation*).
12. **A Novel strategy for sensitizing cancer cells** (Invited talk for IBC's 21st Annual International Conference on Antibody Engineering, San Diego, December 5-9, 2010. *(Organizing committee is providing full funding for the talk)*).
13. **Role of MUC13 mucin in pancreatic cancer** (Invited talk for 2nd Annual Sanford Research/USD Symposium, May 11, 2011), Sioux Falls, SD.
14. **Emerging roles of MUC13 mucin in cancer progression, diagnosis and treatment** (Invited talk at Sanford Research/USD Faculty Seminar Series, Feb 18, 2011), Sioux Falls, SD.

15. **Emerging roles of Transmembrane mucin MUC13 in cancer** (Invited talk at Charles Drew University of Medicine and Science, July 18, 2011), Los Angeles, CA.
16. **Dr. Subhash Chauhan** presented an invited seminar entitled “Role of MUC13 mucin in pancreatic cancer” at Sanford School of Medicine, vermillion
17. **Dr. Subhash Chauhan** presented an invited seminar at PROMISE Lecture Series, Sanford Research/USD entitled “Nano-Radiopharmaceuticals for cancer treatment”
18. Dr. Subhash Chauhan was invited for talk entitled “*Clinico-pathological significance of MUC13 mucin in colon cancer*” and **chaired** a session at 4th International Symposium on Translational Cancer Research December 16-19, 2011, Udaipur, Rajasthan, India.
19. **Dr. Subhash Chauhan** presented an invited seminar at Georgia State University, entitled “Clinico-pathological significance of MUC13 expression in colon cancer” Atlanta, Georgia (2012).
20. **Dr. Subhash Chauhan** presented an invited seminar entitled “Antibody Guided Nano-radiopharmaceuticals for Pancreatic Cancer” at Sanford Research/USD and USD Symposium, Sioux Falls.
21. **Dr. Subhash Chauhan** presented an invited lecture entitled “*MUC13 Mucin in Cancer Progression, Diagnosis and Treatment*” at the Cancer Research Institute Himalayan Institute Hospital Trust, Dehradun, India (05/07/2012).
22. **Dr. Subhash Chauhan** presented an invited lecture entitled “*Role of MUC13 Mucin in Cancer*” at Dr. B.R. Ambedkar Research Centre for Biomedical Research (ACBR), University of Delhi (North Campus), Delhi – 110 007, India (05/14/2012).
23. Dr. Subhash Chauhan presented an invited talk entitled “*MUC13 Mucin in Cancer Progression, Diagnosis and Treatment*” at Sanford Research and SDSU Research Symposium 2012, Sioux Falls, SD.
24. **Dr. Subhash Chauhan** presented SDSU Life Sciences Program Invited Lecture entitled “*Clinical significance of transmembrane mucin MUC13 in Pancreatic Cancer*” at Department of Chemistry and Biochemistry, South Dakota State University, Brookings, South Dakota (09/07/2012).
25. **Dr. Subhash Chauhan** presented Invited Lecture entitled “*Significance of MUC13 Mucin in Pancreatic Cancer*” at College of Engineering and Architecture at North Dakota State University (NDSU), Fargo, North Dakota (09/26/2012).

26. **Dr. Subhash Chauhan** presented Invited Lecture entitled “*MUC13 Mucin and Pancreatic Cancer*” at UND COBRE annual symposium, Grand Forks, North Dakota (10/17/2012).
27. **PI Meeting Presentation: Dr. Subhash Chauhan** presented a seminar entitled “Etiology of cervical cancer in Native American women” to other PI’s with funding from the NCI Center to Reduce Cancer Health Disparities (10/28/2012).
28. **Dr. Subhash Chauhan** presented Invited Lecture entitled “*Clinical significance of transmembrane mucin MUC13 in Pancreatic Cancer*” at College of Pharmaceuticals Sciences, University of Tennessee Health Science Center (UTHSC), Memphis, Tennessee (11/28/2012).
29. **Dr. Subhash Chauhan** presented Invited Lecture entitled “*Clinical significance of transmembrane mucin MUC13 in Pancreatic Cancer*” at Biology Department, Concordia College, Moorhead, MN (12/05/2012).
30. **Dr. Subhash Chauhan** presented Invited Lecture entitled “*Smoking, HPV infection and Cervical Cancer Health Disparity*” at 8th Annual Texas Conference on Health Disparities, Fort Worth, Texas (05/30-31/2013).
31. **Dr. Subhash Chauhan** presented Invited Lecture entitled “*Role of MUC13 Mucin in Pancreatic Cancer. Randolph Cancer Center, West Virginia University, Morgantown, WA*” (12/04/2013).
32. **Dr. Subhash Chauhan** presented Invited Lecture entitled “*Role of MUC13 Mucin in Pancreatic Cancer. Cancer Research Center, University of Tennessee Health Science Center, Memphis, TN*” (01/08/2014).
33. **Dr. Subhash Chauhan** presented Invited Lecture entitled “*Novel therapeutic strategies for pancreatic cancer treatment. Department of Pharmacology Tulane University School of Medicine, New Orleans, LA*” (01/10/2014).
34. **Dr. Subhash Chauhan** presented Invited Lecture entitled “*Diagnosis and treatment of Pancreatic Cancer. Kosten Foundation Focus Group, Memphis, TN*” (03/08/2014).
35. **Dr. Subhash Chauhan** presented Invited Lecture entitled “*Novel Diagnostic and Therapeutic Strategies for Pancreatic Cancer. Department of Physics, University of Memphis, Memphis, TN*” (03/26/2014).

36. **Dr. Subhash Chauhan** presented Invited Lecture entitled “*Novel approaches for cancer Diagnosis and Therapy. Sarasvati Dental College and Hospital, Lucknow, UP, India (07/07/2014).*”
37. **Dr. Subhash Chauhan** presented Invited Lecture entitled “*Novel approaches for cancer treatment. College of Dentistry, University of Tennessee Health Science Center, Memphis, TN (11/18/2014).*”
38. **Dr. Subhash Chauhan** presented Invited Lecture entitled “*Ormeloxifene Nanoparticle Formulation for Pancreatic Cancer. Biomaterial Day 2015, Vanderbilt University, Nashville, TN, (03/23/2014).*”
39. **Dr. Subhash Chauhan** presented Invited Lecture entitled “*Novel Therapeutic Strategies for Pancreatic Cancer. College of Pharmacy, University of Texas, Austin, Texas (04/16/2015).*”
40. **Dr. Subhash Chauhan** presented Invited Lecture entitled “*Development of New Therapeutic Approaches for Pancreatic Cancer. Department of NanoEngineering, University of California San Diego (UCSD), San Diego, CA (05/19/2015).*”
41. **Dr. Subhash Chauhan** presented Invited Lecture entitled “*Development of New Therapeutic Approaches for Pancreatic Cancer. Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center (UNMC), Omaha, NE (08/27/2015).*”
42. **Dr. Subhash Chauhan** presented Invited Grand Round Lecture entitled “**Development of New Therapeutic Approaches for Pancreatic Cancer**”. *Department of Endocrinology, University of Tennessee Health Science Center (UTHSC), Memphis, TN, USA, (10/8/2015)*
43. **Dr. Subhash Chauhan** presented Invited Lecture entitled “**Tumor Targeting Using Nanotechnology Approach**”. *Department of Pediatrics-Research, University of Texas MD Anderson Cancer Center, Houston, Texas, (11/03/2015)*
44. **Dr. Subhash Chauhan** presented Invited Lecture entitled “**Nanotechnology Approach for the Treatment of Pancreatic Cancer**”. *Ponce School of Medicine and Health Sciences, Ponce, Puerto Rico, (12/09/2015)*
45. **Dr. Subhash Chauhan** presented Invited Lecture entitled “**MUC13: A potential diagnostic and Therapeutic Target in Pancreatic Cancer**”. *Department of Pathology University of Tennessee Health Science Center (UTHSC), Memphis, TN, USA, (01/18/2016)*
46. **Dr. Subhash Chauhan** presented Invited Lecture entitled “**Role of MUC13 Mucin in Cancers**”. *Shri Ram Chandra University, Porur, Chennai, India (Feb 3, 2016)*

47. **Dr. Subhash Chauhan** presented Invited Lecture entitled “*Newer Therapeutic Approaches for Pancreatic Cancer Treatment*”. 6th International Translational Cancer Research Conference 2016, Ahemdabad, Gujrat, India (Feb 4-8, 2016)
48. **Dr. Subhash Chauhan** presented Invited **Plenary Lecture** entitled “*Newer Therapeutic Approaches for Pancreatic Cancer Treatment*” 1st International conference on **Human implications of Biotechnology, Patna, Bihar, India (Feb 12-14)**.
49. **Dr. Subhash Chauhan** presented Invited Lecture entitled “*MUC13 Interaction with Receptor Tyrosine Kinase HER2 Drives Pancreatic Ductal Adenocarcinoma Progression. Biomaterial Day 2016, University of Memphis, Memphis, TN, (03/18/2016)*).
50. **Dr. Subhash Chauhan** presented Invited **Key Note Lecture** entitled “*Development of New Therapeutic Approaches for Pancreatic Cancer*” 9th World Drug Delivery Summit Pre-conference Workshop on Recent Advances in Drug Delivery Technology held at University of Tennessee Health Science Center (UTHSC), Memphis, TN, USA, (04/25/2016).
51. **Dr. Subhash Chauhan** presented Invited **Plenary Lecture** entitled “*Newer Therapeutic Approaches for Pancreatic Cancer Treatment*” 1st International conference on **Neutraceuticals and Chronic Diseases, Kachin, Kerala, India (Sep 8-11, 2016)**.
52. **Dr. Subhash Chauhan** presented Invited **Plenary Lecture** entitled “*Newer Therapeutic Approaches for Pancreatic Cancer Treatment*” 1st International conference on **1st Photochemistry and Applications of Natural Products for Human Welfare, Saint Thomas College Thrissur, Kerala, India (Sep 7, 2016)**.
53. **Dr. Subhash Chauhan** presented Invited **Plenary Lecture** entitled “*Therapeutic Approaches for Pancreatic Cancer Treatment*” Center for Interdisciplinary Research In Basic Sciences, **Jamia Melia Islamia University, New Delhi, India (Sep 16, 2016)**.
54. **Dr. Subhash Chauhan** presented Invited **Lecture** entitled “*Comorbidity factors Associated with Human Papillomavirus Infectivity: Implications in Cervical Cancer Health Disparity*” Ninth AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Fort Lauderdale, FL, September 25-28, 2016.
55. **Dr. Subhash Chauhan** presented Invited **Lecture** entitled “*Development of New Therapeutic Approaches for Pancreatic Cancer Treatment*” The State University of New York at Buffalo, Buffalo, NY, (October 20, 2016).

56. **Dr. Subhash Chauhan** presented Invited **Lecture** entitled “*Development of New Therapeutic Approaches for Pancreatic Cancer Treatment*” Double Tree by Hilton, Murfreesboro, TN, The UT-CORNET Cancer Conference (November 9, 2016).
57. **Dr. Subhash Chauhan** presented Invited **Lecture** entitled “*Comorbidity factors Associated with Human Papillomavirus Infectivity: Implications in Cervical Cancer Health Disparity*” Spring 2017 Cancer Research Conference, The Freeman Auditorium, Hamilton Eye Institute, Memphis, TN.
58. **Dr. Subhash Chauhan** presented a **Plenary Lecture** entitled “**Targeting Pancreatic Tumor Microenvironment for Effective Pancreatic Cancer Treatment**” Trends in Biochemical and Biomedical Research: Advances and Challenges (TBBR-2018). Organized by: Department of Biochemistry, Institute of Science, **Banaras Hindu University Varanasi-221005, INDIA** February 13-15, 2018
59. **Dr. Subhash Chauhan** presented a **Key Note Lecture** entitled “**Targeting Pancreatic Tumor Microenvironment for Effective Pancreatic Cancer Treatment**” 3rd International conference on Nutraceuticals and Chronic Diseases, Rishikesh, Uttarakhand, India (Sep 14-16, 2018).
60. **Dr. Subhash Chauhan** presented a **Endocrine Grand Round Seminar** entitled “**Cancer of the Pancreas: Role of MUC13 Mucin and EGFRs Cross-talk**” at UTHSC, Memphis on August 30, 2018.
61. **Dr. Subhash Chauhan** presented a **Plenary Lecture** entitled “**Mechanisms of Social-Epigenomics in Cancer Health Disparity**” at 14th Annual Conference on Health Disparities: Social Epigenomics and Health Disparities held at UNT, Fort Worth, Texas on June 6-7, 2019.

EVENT ORGANIZATION:

1. **Dr. Subhash Chauhan** organized “**Luncheon**” in the honor of Pancreatic Cancer Patients Survivors and delivered a talk on pancreatic cancer at this event (09/14/2014).
2. **Dr. Subhash Chauhan** organized “**Purple Night**” in the honor of Pancreatic Cancer Patients Survivors and delivered a talk on pancreatic cancer at this event (09/12/2015).
3. **Dr. Subhash Chauhan** organized **9th World Drug Delivery Summit Pre-conference Workshop on Recent Advances in Drug Delivery Technology** held at *University of Tennessee Health Science Center (UTHSC), Memphis, TN, USA*, (04/25/2016)
4. **Dr. Subhash Chauhan** organized “**Purple Night**” in the honor of Pancreatic Cancer Patients Survivors and delivered a talk on pancreatic cancer at this event (November 2016).

5. **Dr. Subhash Chauhan** and his research group share the lab research with *Pancreatic Cancer patients and Kosten Foundation members, Memphis, TN, (Monthly)*
6. **Dr. Subhash Chauhan** participated as key organizer in **1st International conference on Nutraceuticals and Chronic Diseases, Kachin, Kerala, India (Sep 8-11, 2016).**
7. **Dr. Subhash Chauhan** organized “**Purple Night**” in the honor of Pancreatic Cancer Patients Survivors and delivered a talk on pancreatic cancer at this event (November 2017).
8. **Dr. Subhash Chauhan** participated as key organizer in **2nd International conference on Nutraceuticals and Chronic Diseases, Goa, Goa, India (Sep 1-3, 2017).**
9. **Dr. Subhash Chauhan** served as organizing President for **3rd International conference on Nutraceuticals and Chronic Diseases, Rishikesh, Uttarakhand, India (Sep 14-16, 2018).**
10. **Dr. Subhash Chauhan** organized “**Purple Night**” in the honor of Pancreatic Cancer Patients Survivors and delivered a talk on pancreatic cancer at this event (November 2018).

EDITORIAL APPOINTMENTS:

Associate Editor:

Journal of Nutrition Research

Member Editorial Board:

World Journal of Gastrointestinal Pathophysiology (2010-2015)

Pharmaceutica Analytica Acta (2010-2015)

Journal of Ovarian Research (JOR) (2011-2015)

Journal of Carcinogenesis and Mutagenesis (2013-present)

Journal of Cancer Research (2014- present)

Journal Reviewer:

1. Journal of Nuclear Medicine (JNM)

2. European Journal Nuclear Medicine and Molecular Imaging (EJNMMI)

3. Molecular Cancer Therapeutics (MCT)
4. Fertility Sterility
5. Cancer Chemotherapy and Pharmacology
6. Journal of Biomedical Nanotechnology
7. International Journal of Andrology
8. Molecular and Cellular Biochemistry
9. Future Oncology
10. Journal of Ovarian Research
11. Cancer Research
12. Public Health
13. Experimental and Molecular Pathology
14. Oncotarget
15. Oncogene

COMMITTEES AND OFFICES HELD:

1. OB/GYN CME Planning Task Force Committee (2008 to present)
2. Basic Biomedical Science Graduate Student Committee (2008 to present)
3. Health Affairs Informatics Committee, 2010
4. Member Sanford Health IRB (3) (2010-2013)
5. Member Sanford Research/USD EHS Committee (2010-2013)
6. College of Pharmacy Research Committee (2013-June 2019)
7. **Vice-chair** on College's Research and Graduate Education Committees (2014-June 2019)
8. College of Pharmacy Dean's advisory committee (2014-June 2018)
9. Member UTHSC outstanding mentor Academy
10. Member UTHSC Vice Chancellor Research Cabinet (2017-June 2019)
11. Chair UTHSC Vice Chancellor Basic Research Committee (2017-June 2019)

OTHER PROFESSIONAL AFFILIATIONS AND ACTIVITIES: (OPTIONAL)

RESIDENTS/FELLOWS/GRADUATE STUDENTS TRAINED:

Research Associates/Post-Doctoral Fellows

1. Larissa Back, RA (November 2005 to June 2006, admitted to Medical School)
2. Kelly Vannatta, RA (June 2006 to 2007, admitted to PA School)
3. Diane Maher, Post-Doctoral Fellow (September 2006 to June 2013)
4. Mara Ebeling, RA (August 2007-present)
5. Christina Stangel, RA (August 2007-present, admitted to Medical School)
6. **Dr. Murali Mohan Yallapu, Postdoctoral Fellow (October 2007 to 2015; now independent Faculty at UTHSC)**
7. Brij K. Gupta, PhD student (May 2008-2013) (Graduated in May 2013)
8. Neeraj Chauhan, PhD student (August 2010-present)
9. **Sheema Khan, PhD, Post-Doctoral Fellow (October 2011-2015 now Junior Faculty at UTHSC)**
10. Mohd. Sikander, PhD, Post-Doctoral Fellow (November 2011-present)
11. **Mohd. Saif Zaman, PhD, Post-Doctoral Fellow (July 2012-2015; Now lead Scientist in a Pharmaceutical Company)**
12. Vaibhav Gandhi, BTech, MTech, Graduate Student (2014-present)
13. Saini Setua, BTech, MTech, Graduate Student (2014-present)
14. Sonam Kumari, BTech, MTech, Graduate Student (2014-present)
15. Mariatou Sisay, BS, PharmD Student (2014-present)
16. **Bilal B. Hafeez, PhD, Junior Faculty (July 2015-present)**
17. Ninoy Dan, BTech, MTech, Graduate Student (2016-present)
18. Kyle Dexter, BS, Graduate Student (2016-present)
19. Andrew Messey, BS, Graduate Student (2016-present)

Medical Residents

1. Saleha Niaz, MD. Internal Medicine Resident (2006)
2. Valerie Schultz (Fourth year medical student) (2006)

3. Preetha Nair, MD. Internal Medicine Resident (2007)
4. Preethi Prakash MD. Internal Medicine Resident (2007)
5. Sana Ullah, MD. Internal Medicine Resident (2008)
6. Douglas Mitch, MD. (Fourth Year Medical Student)
7. Robert Buresh, MD. (Pathology Resident)
8. Rashmi Verma, MD. Internal Medicine Resident (September 2009)
9. Kabir Khan, MD. Internal Medicine Resident (September 2012)

Summer Students

1. Sarah Radel, BS (BRIN Summer student, 2006, working as RA at present)
2. Kristina Wattier, BS (BRIN Summer student, 2006, admitted to Medical School)
3. Jordan Nordquist (Summer Student, 2008, admitted to Medical School)
4. Mitchell Ray Dobberphul (Summer Student, 2008, admitted to Medical School)
5. Kathy (Summer Student, 2008, admitted to Medical School)
6. Amy (Summer Student, 2009)
7. Arunima Chandra (BRIN summer student 2009)
8. Mitchell Ray Dobberphul (Medical Research Forum Medical Student, 2009)
9. Jordan Nordquist (Scholarship Pathway Medical Student, 2009)
10. Amanda Schaefer (BRIN summer student 2011)
11. Emily Gaster (summer student 2011)
12. Hilary Newby (summer student 2012)
13. Amber Evenson (summer student 2012)
14. Nia Johnson (summer student 2014)

Resident and Intern (while in UTHSC)

Resident

14. Deepti Haskoppal

Interns/volunteers

15. Ankita Shah, BS
16. Bhavin Chauhan, BS
17. Swathi Balakrishna, MS
18. Sonam Kumari, MS (prospective PhD student)

Graduate committee member:

1. Na Lu Smith
2. Michelle Phillip
3. Dan K. Cheng
4. Sanam Sane
5. Joshua Hughes
6. Aditya Ganju
7. Qinghui Wang
8. Benjamin Patters
9. Sabina Ranjit
10. Kinsie Arnst

RESEARCH AND OTHER EXTERNAL SUPPORT:

1R01CA204552-01 NIH/NCI (Chauhan-PI) 07/11/2016-05/31/2021

Project Title: MUC13 Mucin in Colorectal Cancer Health Disparity

NIH/NCI

To investigate role of MUC13 mucin in colorectal cancer health disparity and evaluate its diagnostic/prognostic potential.

Total award: 1.7 M

1R01CA210192-01 NIH/NCI (Chauhan-PI) 06/24/2016 – 05/31/2021

Project Title: Targeted Nanotherapy for Pancreatic Cancer

To evaluate efficacy of a targeted nanoparticle formulation for pancreatic cancer treatment alone and combination with Gemcitabine.

Total award: 1.7 M

1R01CA206069-01A1 NIH/NCI (Chauhan-PI) 06/24/2016 – 05/31/2021

Project Title: Development of a Targeted Nanotechnology Platform for Pancreatic Cancer

To develop a curcumin loaded magnetic nanoparticle formulation for altered tumor microenvironment and chemo-sensitization of pancreatic cancer.

Total award: 1.7 M

1U01CA162106-01A1 NIH/NCI (PI: Chauhan, Jaggi, co-PI) 06/21/12 - 06/20/17

Project Title: Etiology of cervical cancer health disparity in American Indian women

To study the effects of smoking on HPV infection and cervical cancer progression in American Indian women.

Total award: 1.6 M

DOD PC130870 (Chauhan-PI) 09/21/2014-08/20/2017

Project Title: A Novel Therapeutic Modality for Advanced Stage Prostate Cancer Treatment

To investigate the ormeloxifene use in prostate cancer therapeutics.

Total award: 0.5 M

UT 14-0558 Kosten Foundation, Memphis (PI:
Chauhan) 03/01/14-02/28/17

Project Title: Pancreatic Cancer Research Support Funds

Total award:0.25 M

Brief Title Aspects of MUC13 Mucin in Cancer (R01 CA142736-01A1
NCI/NIH)

Name of PI*: Subhash C. Chauhan

Sponsor/Funding source: NCI/NIH Award start and end dates: 07/01/10 - 06/30/14

Your Role (PI, Co-PI, Co-I): PI % effort on grant: 20%

Award amount for this academic year: \$200,000 Award amount to the
College: \$200,000 Total award: 1.1 M

Brief Title Etiology of Aggressive Cervical Cancer Health Disparity in American
Indian Women

Name of PI*: Subhash C. Chauhan

Sponsor/Funding source: NCI/NIH Award start and end dates: 06/21/12 - 06/20/17

Your Role (PI, Co-PI, Co-I): PI % effort on grant: 20%

Award amount for this academic year: \$207,000 Award amount to the
College: \$207,000 Total award: 1.5M

Pancreatic Cancer Treatment

Name of PI: Subhash Chauhan Submission date: 12/20/2013

Your Role: PI Sponsor/Funding source: Kosten Foundation

Total award: \$10,000

Pancreatic Cancer Treatment

Name of PI: Subhash Chauhan Submission date: 08/16/2014-08/15/2015

Your Role: PI Sponsor/Funding source: Kosten Foundation

Total award: \$30,000/year (This funding is initially for one year but likely to be
continued for next five years).

1S10OD016226-01A1 Bernd Meibohm (PI) 4/2014-4/2015

Brief Title: Mass spectrometer for small molecule drug development

This shared instrumentation application is for an AB Sciex Triple Quad 4500 triple
quadrupole mass spectrometer as replacement for an outdated shared liquid
chromatography-mass spectrometry instrument.

Role: Co-investigator

PENDING SUPPORT:

COMPLETED RESEARCH SUPPORT/GRANTS (Total 9):

1P20RR024219-01A1 (Miskimins – PI; Chauhan – Project PI/Core D Co-Director) 55%
effort

NIH/NCRR 05/01/10 – 04/30/15 Total - \$7,500,000 (Graduated from the project in 2013 upon receiving RO1 and UO1 NIH grants)

Center for Cancer Biology Research

Project Title: Antibody Guided Nano-Radiopharmaceuticals for Pancreatic Cancer

Our overall goal is to develop new strategies for treating pancreatic cancer (PanCa) by combining nanoparticle technology with targeted radioimmunotherapy (RIT). Aims: 1) To determine the loading and release characteristics of polylactide-co-glycolide nanoparticles (PLGA-NPs) laden with gemcitabine, paclitaxel, or cisplatin; and to investigate the effects of these particles on the growth of PanCa cell lines. 2) To conjugate PanCa-specific antibodies to drug loaded PLGA-NPs and evaluate the therapeutic efficacy of these formulations in PanCa cell lines and a mouse model. 3) To generate radiolabeled PanCa-specific antibodies conjugated to drug loaded PLGA-NPs and determine their biodistribution and therapeutic efficacy in a PanCa mouse model. This project will have a significant impact toward efforts to develop novel and targeted therapies for PanCa.

Overlap: None

3SB161 (PI: Lee; Project PI: Chauhan) 07/01/09 - 03/31/13

South Dakota State Legislature, Governor's 2010 Initiative

Translational Cancer Research Center-Impacting the Cancer Care of South Dakotans (Rural Underserved and Native Americans) Project Title: Profiling breast cancer markers in American Indian women

To investigate the expression pattern of some known breast cancer markers along with investigating differentially expressed genes in American Indian versus Caucasian women to determine why breast cancer is so aggressive and fatal in this population.

1R01CA142736-01A1 (PI: Chauhan) 07/01/10 - 06/30/14

NIH/NCI

KG100497 (PI: Miskimins) 05/01/10 – 04/30/13

Susan G. Komen for the Cure

Targeting Metabolic Processes in Breast Cancer Cells

The major goals of this grant are to determine how metformin kills breast cancer cells and to discover mechanisms to enhance death in resistant cancer cells in vitro and in vivo.

Role: Collaborator

37392 (PI: Chauhan) 08/01/10 - 07/31/12(no-cost extension)

Merck Pharmaceuticals

Association of Human Papillomavirus Infection with Prostate Cancer in American Indians

To determine if HPV infection status in the prostate cancer tissue of American Indian men and to examine its association with prostate cancer. Also to determine the incidence of HPV infection in this population and to improve general awareness of HPV and PSA screening.

PC073887 (PI: Chauhan) 04/01/08 - 03/31/11 (1 year No cost extension)

Department of Defense

PSMA targeted nano-radioimmunotherapy for prostate cancer

This project is aimed at improving efficacy of RIT for prostate cancer. In project we will combine nanotechnology, RIT for improving efficacy of PSMA based RIT.

PC073643 (PI: Jaggi) 04/01/08 - 03/31/11 (1 year No cost extension)

Department of Defense

Modulation of Beta-Catenin Activity with PKD1 in Prostate Cancer

In this project we propose to investigate how PKD1 modulate beta-catenin activity in prostate cancer cells.

Role: Collaborator

1P20 MD001631 (PI EXPORT Project - Chauhan) 07/01/07 - 06/30/08
NIH, NCMHD

Role of myotonic dystrophy protein kinase (DMPK) in cervical cancer in American Indian women

To determine the expression profile of DMPK in cervical cancer samples of American Indian women and to investigate DMPK function in cervical cancer.

408021 (PI – Chauhan) 04/01/06 - 03/31/07

Role of MUC13 in Ovarian Cancer Progression

To analyze the expression pattern of MUC13 in ovarian cancer samples.

P20 RR016479 (PI – Jaggi) 07/01/06 - 06/30/07

Effect of PKD1 and β -catenin interaction on proliferation of prostate cancer cells.

To determine the effect of PKD1 knock-down on β -catenin subcellular localization and Wnt signaling.

Role: Co-PI

BOOKS AND BOOK CHAPTERS:

1. **Chauhan SC.**, Jaggi M., Bell MC., Verma M. and Kumar D. Epidemiology of human papilloma virus (HPV) in cervical mucosa. *“Cancer Epidemiology”* Vol.1: 439-456. Humana Press, Editor(s): Dr. Mukesh Verma)
2. Maher DM., Bell MC., **Chauhan SC.** Control of Human Papillomavirus gene expression by transcription factors and the upstream regulatory region *“Current Advances in Gynecological Oncology”* **Editor(s):** Dr. Subhash C. Chauhan and Deepak Kumar, **Co-editors:** Meena Jaggi and Maria C. Bell. Research Signpost Publications, PP 119-142
3. Gunn A J., Howard T., Jaggi M. and **Chauhan SC.** Current imaging strategies in the diagnosis of ovarian cancer *“Current Advances in Gynecological Oncology”* **Editor(s):** Dr. Subhash C. Chauhan and Deepak Kumar, **Co-editors:** Meena Jaggi and Maria C. Bell. Research Signpost Publications, PP 47-64
4. Hughes JE., **Chauhan SC.** and Jaggi M. The Interplay between Cellular Adhesion Molecules and Cervical Cancer *“Current Advances in Gynecological Oncology”* **Editor(s):** Dr.

Subhash C. Chauhan and Deepak Kumar, **Co-editors:** Meena Jaggi and Maria C. Bell. Research Signpost Publications, PP 93-108

5. Sundram V., **Chauhan SC.** Kumar D. and Jaggi M. Signaling pathways modulated by curcumin in cervical cancer “*Current Advances in Gynecological Oncology*” **Editor(s):** Dr. Subhash C. Chauhan and Deepak Kumar, **Co-editors:** Meena Jaggi and Maria C. Bell. Research Signpost Publications, PP 143-162
6. Yallapu MM., Jaggi M and **Chauhan SC.** Design of Nanoparticle Mediated Targeted Drug Delivery: Ovarian Cancer Perspective “*Current Advances in Gynecological Oncology*” **Editor(s):** Dr. Subhash C. Chauhan and Deepak Kumar, **Co-editors:** Meena Jaggi and Maria C. Bell. Research Signpost Publications, PP 209-244
7. Kumar D., Srivastava A., **Chauhan SC.** and Verma M. MicroRNAs in Gynecological. Cancers. “*Current Advances in Gynecological Oncology*” **Editor(s):** Dr. Subhash C. Chauhan and Deepak Kumar, **Co-editors:** Meena Jaggi and Maria C. Bell. Research Signpost Publications, PP 81-92
8. Verma M., **Chauhan SC.** and Kumar D. Environmental factors in gynecological cancers. “*Current Advances in Gynecological Oncology*” **Editor(s):** Dr. Subhash C. Chauhan and Deepak Kumar, **Co-editors:** Meena Jaggi and Maria C. Bell Research Signpost Publications, PP 109-118
9. **Chauhan SC.**, Kumar D, Bell MC, Verma M, and Jaggi M. Current Trends in Ovarian Cancer Diagnostics and Therapeutics. “*Current Advances in Gynecological Oncology*” **Editor(s):** Dr. Subhash C. Chauhan and Deepak Kumar, **Co-editors:** Meena Jaggi and Maria C. Bell. Research Signpost Publications, PP 1-28
10. Pluronic Nanotechnology for Overcoming Drug Resistance. Pallabita Chowdhury, Prashanth K.B. Nagesh, Santosh Kumar, Meena Jaggi, **Subhash C. Chauhan**, and Murali M. Yallapu* In Bioactivity of engineered nanoparticles (Editors: Bing Yan, Hongyu Zhou, and Jorge Gardea-Torresdey), Publisher Springer, 2017.
11. Multifunctional magnetic nanoparticles for cancer treatment. Saini Setua, Meena Jaggi, Murali M. Yallapu*, **Subhash C. Chauhan*** in Nanotechnologies in Preventive and Regenerative Medicine (Editor: Vuk Uskokovic), Publisher Elsevier, 2017

Book(s) Edited

1. ***Current Advances in Gynecological Oncology.*** **Editor(s):** Dr. Subhash C. Chauhan and Deepak Kumar, **Co-editor(s):** Meena Jaggi and Maria C. Bell, Publisher: Research Signpost/Transworld Research Network

PEER-REVIEWED JOURNAL ARTICLES:

1. Massey AE, Sikander M, Chauhan N, Kumari S, Setua S, Shetty AB, Mandil H, Kashyap VK, Khan S, Jaggi M, Yallapu MM, Hafeez BB, Chauhan SC. Next-generation paclitaxel-nanoparticle formulation for

- pancreatic cancer treatment. *Nanomedicine*. 2019 Jun 4;102027. doi: 10.1016/j.nano.2019.102027. PMID: 31170509.
2. Khan S, Setua S, Kumari S, Dan N, Massey A, Hafeez BB, Yallapu MM, Stiles ZE, Alabkaa A, Yue J, Ganju A, Behrman S, Jaggi M, Chauhan SC. Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. *Biomaterials*. 2019 Jul;208:83-97. doi:10.1016/j.biomaterials.2019.04.005. Epub 2019 Apr 8. PubMed PMID: 30999154.
 3. Sikander M, Malik S, Chauhan N, Khan P, Kumari S, Kashyap VK, Khan S, Ganju A, Halaweish FT, Yallapu MM, Jaggi M, Chauhan SC. Cucurbitacin D Reprograms Glucose Metabolic Network in Prostate **Cancer**. *Cancers (Basel)*. 2019 Mar 14;11(3). pii:E364. doi: 10.3390/cancers11030364. PubMed PMID: 30875788; PubMed Central PMCID: PMC6469021.
 4. Romero LO, Massey AE, Mata-Daboin AD, Sierra-Valdez FJ, Chauhan SC, Cordero-Morales JF, Vásquez V. Dietary fatty acids fine-tune Piezo1 mechanical response. *Nature Communication*. 2019 Mar 13;10(1):1200. doi: 10.1038/s41467-019-09055-7. PubMed PMID: 30867417; PubMed Central PMCID: PMC6416271.
 5. Chowdhury P, Nagesh PKB, Hatami E, Wagh S, Dan N, Tripathi MK, Khan S, Hafeez BB, Meibohm B, Chauhan SC, Jaggi M, Yallapu MM. Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells. *J Colloid Interface Sci*. 2019 Feb 1;535:133-148. doi: 10.1016/j.jcis.2018.09.072. Epub 2018 Sep 22. PubMed PMID: 30292104.
 6. Tripathi MK, Zacheaus C, Doxtater K, Keramatnia F, Gao C, Yallapu MM, Jaggi M, Chauhan SC. Z Probe, An Efficient Tool for Characterizing Long Non-Coding RNA in FFPE Tissues. *Noncoding RNA*. 2018 Sep 5;4(3). pii: E20. doi:10.3390/ncrna4030020. PubMed PMID: 30189670; PubMed Central PMCID: PMC6162476.
 7. Nagesh PKB, Chowdhury P, Hatami E, Boya VKN, Kashyap VK, Khan S, Hafeez BB, Chauhan SC, Jaggi M, Yallapu MM. miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy. *Cancers (Basel)*. 2018 Aug 25;10(9). pii: E289. doi: 10.3390/cancers10090289. PubMed PMID: 30149628; PubMed Central PMCID: PMC6162422.
 8. Stiles ZE, Khan S, Patton KT, Jaggi M, Behrman SW, Chauhan SC. Transmembrane mucin MUC13 distinguishes intraductal papillary mucinous neoplasms from non-mucinous cysts and is associated with high-risk lesions. *HPB (Oxford)*. 2018 Aug 13. pii: S1365-182X(18)32694-7. doi: 10.1016/j.hpb.2018.07.009. [Epub ahead of print] PubMed PMID: 30115565.
 9. Chowdhury P, Nagesh PKB, Khan S, Hafeez BB, Chauhan SC, Jaggi M, Yallapu MM. Development of polyvinylpyrrolidone/paclitaxel self-assemblies for breast cancer. *Acta Pharm Sin B*. 2018 Jul;8(4):602-614. doi: 10.1016/j.apsb.2017.10.004. Epub 2017 Dec 10. PubMed PMID: 30109184; PubMed Central PMCID: PMC6090082.
 10. Hatami E, Nagesh PKB, Chowdhury P, Chauhan SC, Jaggi M, Samarasinghe AE, Yallapu MM. Tannic Acid-Lung Fluid Assemblies Promote Interaction and Delivery of Drugs to Lung Cancer Cells. *Pharmaceutics*. 2018 Aug 1;10(3). pii: E111. doi: 10.3390/pharmaceutics10030111. PubMed PMID: 30071698; PubMed Central PMCID: PMC6161105.
 11. Almadadi HM, Nagesh PKB, Sahay P, Bhandari S, Eckstein EC, Jaggi M, Chauhan SC, Yallapu MM, Pradhan P. Optical study of chemotherapy efficiency in cancer treatment via intracellular structural disorder analysis using partial wave spectroscopy. *J Biophotonics*. 2018 Dec;11(12):e201800056. doi: 10.1002/jbio.201800056. Epub 2018 Sep 26. PubMed PMID: 29869394.
 12. Tripathi MK, Doxtater K, Keramatnia F, Zacheaus C, Yallapu MM, Jaggi M, Chauhan SC. Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes. *Drug Discov Today*. 2018 Apr 23. pii: S1359-6446(18)30071-0. doi: 10.1016/j.drudis.2018.04.010. [Epub ahead of print] Review. PubMed PMID: 29698834.

13. Dan N, Setua S, Kashyap VK, Khan S, Jaggi M, Yallapu MM, Chauhan SC. Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. *Pharmaceuticals* (Basel). 2018 Apr 9;11(2). pii: E32. doi: 10.3390/ph11020032. Review. PubMed PMID: 29642542.
14. Nagesh PKB, Hatami E, Chowdhury P, Kashyap VK, Khan S, Hafeez BB, Chauhan SC, Jaggi M, Yallapu MM. Tannic Acid Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in Prostate Cancer. *Cancers* (Basel). 2018 Mar 7;10(3). pii: E68. doi: 10.3390/cancers10030068. PubMed PMID: 29518944; PubMed Central PMCID: PMC5876643.
15. Awasthee N, Rai V, Chava S, Nallasamy P, Kunnumakkara AB, Bishayee A, Chauhan SC, Challagundla KB, Gupta SC. Targeting IkappaB kinases for cancer therapy. *Semin Cancer Biol.* 2018 Feb 24. pii: S1044-579X(17)30046-9. doi: 10.1016/j.semcancer.2018.02.007. [Epub ahead of print] Review. PubMed PMID: 29486318.
16. Kumari S, Khan S, Gupta SC, Kashyap VK, Yallapu MM, Chauhan SC, Jaggi M. MUC13 contributes to rewiring of glucose metabolism in pancreatic cancer. *Oncogenesis.* 2018 Feb 22;7(2):19. doi: 10.1038/s41389-018-0031-0. PubMed PMID: 29467405; PubMed Central PMCID: PMC5833644.
17. Ganju A, Chauhan SC, Hafeez BB, Doxtater K, Tripathi MK, Zafar N, Yallapu MM, Kumar R, Jaggi M. Protein kinase D1 regulates subcellular localisation and metastatic function of metastasis-associated protein 1. *Br J Cancer.* 2018 Feb 20;118(4):587-599. doi: 10.1038/bjc.2017.431. Epub 2018 Feb 20. PubMed PMID: 29465084; PubMed Central PMCID: PMC5830591.
18. Khan S, Zafar N, Khan SS, Setua S, Behrman SW, Stiles ZE, Yallapu MM, Sahay P, Ghimire H, Ise T, Nagata S, Wang L, Wan JY, Pradhan P, Jaggi M, Chauhan SC. Clinical significance of MUC13 in pancreatic ductal adenocarcinoma. *HPB (Oxford).* 2018 Jan 15. pii: S1365-182X(17)31184-X. doi: 10.1016/j.hpb.2017.12.003. [Epub ahead of print] PubMed PMID: 29352660.
19. Sahay P, Ganju A, Almabadi HM, Ghimire HM, Yallapu MM, Skalli O, Jaggi M, Chauhan SC, Pradhan P. Quantification of photonic localization properties of targeted nuclear mass density variations: Application in cancer-stage detection. *J Biophotonics.* 2017 Dec 9. doi: 10.1002/jbio.201700257. [Epub ahead of print] PubMed PMID: 29222925.
20. Setua S, Khan S, Doxtater K, Yallapu MM, Jaggi M, Chauhan SC. miR-145: Revival of a Dragon in Pancreatic Cancer. *J Nat Sci.* 2017 Mar;3(3). pii: e332. PubMed PMID: 28616589; PubMed Central PMCID: PMC5467535.
21. Hafeez BB, Ganju A, Sikander M, Kashyap VK, Hafeez ZB, Chauhan N, Malik S, Massey AE, Tripathi MK, Halaweish FT, Zafar N, Singh MM, Yallapu MM, Chauhan SC, Jaggi M. Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic β -catenin Signaling and EMT Progression. *Mol Cancer Ther.* 2017 Oct;16(10):2267-2280. doi: 10.1158/1535-7163.MCT-17-0157. Epub 2017 Jun 14. PubMed PMID: 28615299; PubMed Central PMCID: PMC5774234.
22. Chowdhury P, Roberts AM, Khan S, Hafeez BB, Chauhan SC, Jaggi M, Yallapu MM. Magnetic nanoformulations for prostate cancer. *Drug Discov Today.* 2017 Aug;22(8):1233-1241. doi: 10.1016/j.drudis.2017.04.018. Epub 2017 May 16. Review. PubMed PMID: 28526660; PubMed Central PMCID: PMC5565688.
23. Karuri AR, Kashyap VK, Yallapu MM, Zafar N, Kedia SK, Jaggi M, Chauhan SC. Disparity in rates of HPV infection and cervical cancer in underserved US populations. *Front Biosci* (Schol Ed). 2017 Jun 1;9:254-269. Review. PubMed PMID: 28410118.
24. Boya VN, Lovett R, Setua S, Gandhi V, Nagesh PK, Khan S, Jaggi M, Yallapu MM*, Chauhan SC*. Probing mucin interaction behavior of magnetic nanoparticles. *J Colloid Interface Sci.* 488:258-268, 2017.
25. Ganju A, Khan S, Hafeez BB, Behrman SW, Yallapu MM*, Chauhan SC*, Jaggi M*. miRNA nanotherapeutics for cancer. *Drug Discov Today.* 22(2):424-432, 2017.

26. Karuri AR, Kashyap VK, Yallapu MM, Zafar N, Kedia SK, Jaggi M, **Chauhan SC***. Disparity in rates of HPV infection and cervical cancer in underserved US populations. *Front Biosci* (Schol Ed). 2017 Jun 1;9:254-269.
27. Sikander M, Hafeez BB, Malik S, Alsayari A, Halaweish FT, Yallapu MM, **Chauhan SC***, Jaggi M. Cucurbitacin D exhibits potent anti-cancer activity in cervical cancer. *Sci Rep*. 8;6:36594, 2017.
28. Setua S, Khan S, Yallapu MM, Behrman SW, Sikander M, Khan SS, Jaggi M, **Chauhan SC**. Restitution of Tumor Suppressor MicroRNA-145 Using Magnetic Nanoformulation for Pancreatic Cancer Therapy. *J Gastrointest Surg*. 21(1):94-105, 2017.
29. Khan S, Sikander M, Ebeling MC, Ganju A, Kumari S, Yallapu MM, Hafeez BB, Ise T, Nagata S, Zafar N, Behrman SW, Wan JY, Ghimire HM, Sahay P, Pradhan P, **Chauhan SC***, Jaggi M*. MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression. *Oncogene* (Nature Publishing Group). 36(4):491-500, 2017.
30. Saini Setua, Sheema Khan, Kyle Doxtater, Murali M. Yallapu, Meena Jaggi, and **Subhash C. Chauhan**. miR-145: Revival of a Dragon in Pancreatic Cancer. *Journal of Nature and Science (JNSCI)*, 3(3):e332, 2017
31. Setua S, Khan S, Yallapu MM, Behrman SW, Sikander M, Khan SS, Jaggi M, **Chauhan SC**. Restitution of Tumor Suppressor MicroRNA-145 Using Magnetic Nanoformulation for Pancreatic Cancer Therapy. *J Gastrointest Surg*. 2016 Aug 9. [Epub ahead of print] PubMed PMID: 27507554.
32. Khan S, Sikander M, Ebeling MC, Ganju A, Kumari S, Yallapu MM, Hafeez BB, Ise T, Nagata S, Zafar N, Behrman SW, Wan JY, Ghimire HM, Sahay P, Pradhan P, **Chauhan SC**, Jaggi M. MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression. *Oncogene*. 2016 Jun 20. doi:10.1038/onc.2016.218. [Epub ahead of print] PubMed PMID: 27321183
33. Nagesh PK, Johnson NR, Boya VK, Chowdhury P, Othman SF, Khalilzad-Sharghi V, Hafeez BB, Ganju A, Khan S, Behrman SW, Zafar N, **Chauhan SC**, Jaggi M, Yallapu MM. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. *Colloids Surf B Biointerfaces*. 2016 Mar 26;144:8-20. doi: 10.1016/j.colsurfb.2016.03.071. [Epub ahead of print] PubMed PMID: 27058278.
34. Zaman MS, Chauhan N, Yallapu MM, Gara RK, Maher DM, Kumari S, Sikander M, Khan S, Zafar N, Jaggi M, **Chauhan SC**. Curcumin Nanoformulation for Cervical Cancer Treatment. *Sci Rep*. 2016 Feb 3;6:20051. doi: 10.1038/srep20051. PubMed PMID: 26837852; PubMed Central PMCID: PMC4738284.
35. Khan S, Jaggi M, **Chauhan SC**. Revisiting stroma in pancreatic cancer. *Oncoscience*. 2015 Aug 21;2(10):819-20. *eCollection* 2015. PubMed PMID: 26682261; PubMed Central PMCID: PMC4671936.
36. Yallapu MM, Nagesh PK, Jaggi M, **Chauhan SC**. Therapeutic Applications of Curcumin Nanoformulations. *AAPS J*. 2015 Nov;17(6):1341-56. doi: 10.1208/s12248-015-9811-z. Epub 2015 Sep 3. PubMed PMID: 26335307; PubMed Central PMCID: PMC4627456.
37. Khan S, Ebeling MC, Chauhan N, Thompson PA, Gara R, Ganju A, Yallapu MM, Behrman SW, Zhao H, Zafar N, Singh MM, Jaggi M, **Chauhan SC***, Ormeloxifene Suppresses Desmoplasia and Enhances Sensitivity of Gemcitabine in Pancreatic Cancer. *Can Res*, 2015, 1:75(11):2292-304. PMID: 25840985.
38. Yallapu MM, Nagesh PK, Jaggi M, Chauhan SC. Therapeutic Applications of Curcumin Nanoformulations. *AAPS J*. 2015 Sep 3. [Epub ahead of print] PubMed PMID:26335307
39. El-Senduny FF, Badria FA, El-Waseef AM, Chauhan SC, Halaweish F. Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B. *Tumour Biol*. 2015 Aug 5. [Epub ahead of print] PubMed PMID: 26242260

40. Khan S, Chauhan N, Yallapu MM, Ebeling MC, Balakrishna S, Ellis RT, Thompson PA, Balabathula P, Behrman SW, Zafar N, Singh MM, Halaweish FT, Jaggi M, **Chauhan SC***, Nanoparticle formulation of ormeloxifene for pancreatic cancer. *Biomaterials*, 2015, 53:731-743
41. Yallapu MM, Chauhan N, Othman SF, Khalilzad-Sharghi V, Ebeling MC, Khan S, Jaggi M, **Chauhan SC***. Implications of protein corona on physico-chemical and biological properties of magnetic nanoparticles. *Biomaterials*. 2015, 46:1-12. PubMed PMID: 25678111.
42. Khan S., Ebeling MC., Zaman MS., Sikander M., Yallapu MM., Chauhan N., Yacoubian AM., Behrman SW., Zafar N., Kumar D., Thompson PA., Jaggi M. and **Chauhan SC**. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. *Oncotarget*. 5(17):7599-7609
43. Maher DM, Khan S, Nordquist J, Ebeling MC, Bauer NA, Kopel L, Singh MM, Halaweish F, Bell MC, Jaggi M, Chauhan SC. Ormeloxifene efficiently inhibits ovarian cancer growth. *Cancer Letters*. 2014 Oct 9. pii: S0304-3835(14)00597-7. doi: 10.1016/j.canlet.2014.10.009. [Epub ahead of print] PubMed PMID: 25306892.
44. Ganju A, Yallapu MM., Khan S, Behrman SW., **Chauhan SC** and Jaggi M. Nanoways to Overcome Docetaxel Resistance in Prostate Cancer, *Drug Resistance Updates* (Impact factor 11), 2014 Apr;17(1-2):13-23. doi: 10.1016/j.drug.2014.04.001. Epub 2014 Apr 5. PMID: 24853766
45. Gara RK, Kumari S, Ganju A, Yallapu MM, Jaggi M, **Chauhan SC***. Slit/Robo pathway: a promising therapeutic target for cancer. *Drug Discov Today*. 2014 Sep 19. pii: S1359-6446(14)00357-2. doi: 10.1016/j.drudis.2014.09.008. [Epub ahead of print] Review. PubMed PMID: 25245168.
46. Sundram V, Ganju A, Hughes JE, Khan S, **Chauhan SC**, Jaggi M. Protein kinase D1 attenuates tumorigenesis in colon cancer by modulating β -catenin/T cell factor activity. *Oncotarget*. 2014;5(16):6867-84. PubMed PMID: 25149539.
47. Yallapu MM, Katti KS, Katti DR, Mishra SR, Khan S, Jaggi M, **Chauhan SC***. The Roles of Cellular Nanomechanics in Cancer. *Med Res Rev*. 2014. doi:10.1002/med.21329. [Epub ahead of print] PubMed PMID: 25137233.
48. Yallapu MM, Khan S, Maher DM, Ebeling MC, Sundram V, Chauhan N, Ganju A, Balakrishna S, Gupta BK, Zafar N, Jaggi M, **Chauhan SC***. Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. *Biomaterials*. 2014;35(30):8635-48. doi: 10.1016/j.biomaterials.2014.06.040. Epub 2014 Jul 12. PubMed PMID: 25028336.
49. Rezvani K, Sane S, Boudreau D, Gupta BK, Autenried R, Wang X, Wang H, Schlenker E, Zhang D, Telleria C, Huang L, **Chauhan SC**, and Abdullah A. Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell death by interfering with the p53-Mortalin interactions in colon cancer cells. *Cell Death & Disease* 2014 13;5:e1118. doi: 10.1038/cddis.2014.100.
50. Gupta BK., Maher DM., Ebeling MC., Stephenson PD., Puumala SE., Koch MRD., Aburatani H., Jaggi M and **Chauhan SC***. Functions and regulation of MUC13 mucin in colon cancer cells. *Journal of Gastroenterology* (In Press). PMID: 24097071
51. Khan S., Ansarullah., Kumar D., Jaggi M. and **Chauhan SC***. Targeting microRNAs in pancreatic cancer: microplayers in the big game. *Cancer Research*, 2013; 15;73(22):6541-7. PMID: 24204026
52. Srivastava, A., Goldberger, H., Dimtchev, A., Ramalinga, M., Chijioke, J., Marian, C., Oermann, E., Uhm, S., Kim, J.S., Chen, L.N., Li, X., Berry, D.L., Kallakury, B.V.S., **Chauhan, S.C.**, Collins, S.P., Suy, S., Kumar, D., MicroRNA Profiling in Prostate Cancer -The Diagnostic Potential of Urinary miR-205 and miR-214. *PLOS One*, 2013. 8(10):e76994. PMID: 24167554
53. Yallapu MM, Ebeling MC, Jaggi M, **Chauhan SC**. Plasma proteins interaction with curcumin nanoparticles: implications in cancer therapeutics. 2013;14(4):504-15 PMID: 23566382

54. Gara RK, Sundram V., **Chauhan SC.** and Jaggi M. Anti-cancer potential of a novel SERM ormeloxifene. *Current Medicinal Chemistry* 2013; 20(33):4177-84. PMID 23895678
55. Yallapu MM., Ebeling MC., Khan S., Sundram V., Chauhan N., Gupta BK., Puumala SE., Jaggi M and **Chauhan SC.** Novel curcumin loaded magnetic nanoparticles for pancreatic cancer treatment. *Molecular Cancer Therapeutics* 2013; 8: 1471-80. PMID 23704793
56. Yallapu MM., Jaggi M, and **Chauhan SC***. Curcumin Nanomedicine: A Road to cancer therapeutics. *Current Pharmaceuticals Designs* 2013 19(11):1994-2010. PMID: 23116309
57. Zaman MS., Maher DM., Khan S., Jaggi M. and **Chauhan SC***. Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. *J Ovarian Res.* 2012 Dec 13;5(1):44.
58. Gupta BK, Maher DM, Ebeling MC, Sundram V, Koch MD, Lynch DW, Bohlmeier T, Watanabe A, Aburatani H, Puumala SE, Jaggi M, **Chauhan SC***. Increased expression and aberrant localization of mucin 13 in metastatic colon cancer. *J Histochem Cytochem.* 2012 Nov;60(11):822-31 PMID: 22914648
59. Yallapu MM., Othman SF., Curtis ET., Nichole AB., Chauhan N., Kumar D., Jaggi M and **Chauhan SC.** Curcumin loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. *International Journal of Nanotechnology* 2012;7:1761-79 (***Corresponding Author**)
60. Sundram V., **Chauhan SC.** and Jaggi M. Curcumin attenuates β -catenin signaling in prostate cancer cells through activation of protein kinase D1. *PLoS One* 2012;7(4):e35368
61. **Chauhan SC.**, Ebeling MC., Maher DM., Watanabe A., Koch MD., Aburatani H., Lio Y. and Jaggi M. MUC13 mucin augments pancreatic tumorigenesis. *Molecular Cancer Therapeutics* 2012 11(1):24-33 (**Selected for cover page**) (***Corresponding Author**)
62. Patacsil D., Osayi S., Tran AT., Saenz F., Yimer L., Shajahan AN., Gokhale PC., Verma M., Clarke R., **Chauhan SC.** and Kumar D. Vitamin E Succinate inhibits survivin and induces apoptosis in pancreatic cancer cells. *Genes & Nutrition* 2012 7(1):83-9
63. Yallapu MM., Ebeling MC., Chauhan N., Jaggi M. and **Chauhan SC***. Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes. *International Journal of Nanotechnology* 2011;6:2779-90 (***Corresponding Author**)
64. Schmidt-Grimminger DC, Bel MC, Muller CJ, Maher DM, **Chauhan SC**, Buchwald DS. HPV infection among rural American Indian women and urban White women in South Dakota: an HPV prevalence study. *BMC Infect Dis.* 2011 24;11(1):252
65. Yallapu MM., Doberphool M., Maher DM., Jaggi M. and **Chauhan SC***. Design of Curcumin loaded Cellulose Nanoparticles for Prostate Cancer. *Current Drug Metabolism* 2012;13(1):120-8 (***Corresponding Author**)
66. Yallapu MM., Jaggi M, and **Chauhan SC***. Curcumin Nanoformulations: A Future Nanomedicine for Cancer. *Drug Discovery Today* 2012 Jan;17(1-2):71-80. (***Corresponding Author**)
67. Sundram V., Chauhan SC. and Jaggi M. Emerging roles of protein kinase D1 in cancer. *Molecular Cancer Research* 2011 9(8):985-96.
68. Yallapu MM., Jaggi M, and **Chauhan SC***. Design and engineering of nanogels for cancer treatment. *Drug Discovery Today* 2011; 16(9-10):457-63 (***Corresponding Author**)
69. Yellepeddi VK, Kumar A, Maher DM, **Chauhan SC**, Vangara KK, Palakurthi S. Biotinylated PAMAM Dendrimers for Intracellular Delivery of Cisplatin to Ovarian Cancer: Role of SMVT. *Anticancer Research* 2011;31(3):897-906.
70. Bell MC., Schmidt-Grimminger D., Jacobsen C., **Chauhan SC**, Maher D. and Buchwald D. Risk Factors for HPV Infection among American Indian and White Women in the Northern Plains. *Gynecologic Oncology* 2011; 121(3):532-6.

71. Maher DM., Gupta B.K., Nagata S., Jaggi M, and **Chauhan SC***. MUC13: structure, function and role in cancer pathogenesis. *Molecular Cancer Research* 2011 May;9(5):531-7. (***Corresponding Author**)
72. Maher DM., Bell MC., O'Donnell E., Gupta B.K., Jaggi M, and **Chauhan SC***. Curcumin suppresses Human Papillomavirus oncoproteins, restores expression of p53, pRb and PTPN13 proteins and inhibits benzo[a]pyrene induced upregulation of HPV E7. *Molecular Carcinogenesis* 2011;50(1):47-57. (***Corresponding Author**)
73. Yallapu MM., Othman SF., Curtis ET., Gupta B., Jaggi M and **Chauhan SC**. Multi-functional Magnetic Nanoparticles for Magnetic Resonance Imaging and Cancer Therapy. *Biomaterials* 2011 Mar;32(7):1890-905 (***Corresponding Author**)
74. Yallapu MM., Jaggi M, and **Chauhan SC***. Scope of nanotechnology in ovarian cancer therapeutics. *Journal of Ovarian Research* 2010, Aug 6;3:19 (***Corresponding Author**)
75. Yallapu MM., Gupta B., Jaggi M and **Chauhan SC**. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. *Journal of Colloid & Interface Science* 2010,1;351(1):19-29. (***Corresponding Author**) (**Cover illustration**)
76. Yallapu MM., Jaggi M, and **Chauhan SC***. β -Cyclodextrin-Curcumin Self-assembly Enhances Curcumin Delivery in Prostate Cancer Cells. *Colloids and Surfaces B: Biointerfaces*, 2010 Aug 1;79(1):113-25 (***Corresponding Author**)
77. Yallapu MM., Jaggi M, and **Chauhan SC***.Poly(β -cyclodextrin)-Curcumin Self-assembly : A Novel Approach to Improve Curcumin Delivery and its Therapeutic Efficacy in Prostate Cancer Cells. *Macromolecular Bioscience* 2010, 8;10(10):1141-51. (***Corresponding Author**) (**Cover illustration**)
78. Yallapu MM., Maher DM., Sundram V., Jaggi M, and **Chauhan SC***. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. *Journal of Ovarian Research* 2010 Apr 29;3:11 (***Corresponding Author**)
79. **Chauhan SC***, Kumar D. and Jaggi M. Mucins in ovarian cancer diagnosis and therapy. *Journal of Ovarian Research* 2009 Dec 24;2(1):21 (***Corresponding Author**)
80. **Chauhan SC.**,* Vannatta K., Vinayek N., Watanabe A., Pandey KK., Maher D., Bell MC., Koch MD., Aburatani H., Lio Y. and Jaggi M. Expression and *in vitro* functions of transmembrane mucin MUC13 in ovarian cancer. *Cancer Research* Feb 2009 69(3) 765-774 (***Corresponding Author**)
81. Chauhan SC*, Jaggi M, Bell MC, Verma M, Kumar D. Epidemiology of Human Papilloma Virus (HPV) in Cervical Mucosa. *Methods Mol Biol.* 2009;471:439-56. (***Corresponding Author**)
82. **Chauhan SC.**,* Vinayek N., Dunham K., Lio Y., Koch MD. and Jaggi M. Analysis for MUC1, MUC16 and TAG-72 expression in ovarian cancer: Antigens of multi-targeted antibody guided therapy. *Journal of Histochemistry and Cytochemistry* 2007; 55(8):867-875 (***Corresponding Author**)
83. Chaturvedi P., Singh AP., Chakraborty S., Chauhan SC., Bafna S., Meza JL., Singh PK., Hollingsworth MA., Mehta PP., Batra SK. MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. *Cancer Research* 2008 1;68(7):2065-70
84. Paul M., Jaggi M., Viqar S., **Chauhan SC.**, Hassan S., Biswas H., Balaji K.C. Protein kinase D1 (PKD1) influences androgen receptor (AR) function in prostate cancer cells. *Biochemical and Biophysical Research Communications* 2008 Sep 373:618-23
85. Jaggi BK., **Chauhan SC.** and Jaggi M. Effect of curcumin on signaling pathways in cancer. *Proceedings of South Dakota Academy of Science* 2007 86: 283-293

86. Jaggi M., Chauhan SC., Du C. and Balaji KC. Bryostatin modulates beta-catenin subcellular localization and transcription activity through protein kinase D1 activation *Molecular Cancer Therapeutics* 2008 Sep;7(9):2703-2712. (Cover illustration)
87. Chauhan SC., Kumar D., Bell MC., Koch MD. and Verma M. Molecular Markers of Miscellaneous Primary and Metastatic Tumors of the Uterine Cervix. *European J. Gynecological Oncology* 2007;28(1):5-14.
88. Bell MC., Schmidt-Grimminger D., Patrick S., Ryschon T., Linz L. and *Chauhan SC. Analysis on Human Papillomavirus (HPV) Infection in Women in Northern Plains American Indian Reservation. *Gynecological Oncology* 2007;107(2):236-41 (* Corresponding Author)
89. Venkatraman G, Moorthy PP, Singh AP, Chauhan SC, Johansson SL, Jain M, Smith L, Davis JS, Remmenga SW and Batra SK. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis. *Cancer Letters*, 28;251(2):247-57 Jan 2007.
90. Chauhan SC., Singh AP., Ruiz F., Johansson SL., Jain M., Smith L., Moniaux N. and Batra SK. Aberrant expression of MUC4 in ovarian cancer: Diagnostic significance alone and in combination with MUC1 and MUC16. *Modern Pathology* 19(10):1386-94; Oct 2006.
91. Singh AP., Chauhan SC., Andrianifahanana M., Moniaux N., Meza JL., Copin MC., Hollingsworth MA., Aubert JP. and Batra SK. Inverse association of CFTR and MUC4 in pancreatic adenocarcinoma cells: Regulation of MUC4 by transcriptional and post-translational mechanisms. *Oncogene*, 4;26(1):30-41 Jan 2007.
92. Andrianifahanana M., Chauhan SC., Choudhury A., Moniaux N., Brand RE., Sasson AA., Pour PM. and Batra SK. MUC4-expressing pancreatic adenocarcinomas show elevated levels of both T1 and T2 cytokines: potential pathobiologic implications. *American Journal of Gastroenterology*, 101(10):2319-29 Oct 2006.
93. Moniaux N., Nemos C., Schmied BM., Chauhan SC., Deb S., Morikane K., Choudhury A., Vanlith M., Sutherlin M., Sikela JM., Hollingsworth MA and Batra SK. The human homologue of the RNA polymerase II-associated factor 1 (hPaf1), localized on the 19q13 amplicon, is associated with tumorigenesis. *Oncogene* 1;25(23):3247-57 Jun 2006
94. Singh AP., Chauhan SC., Johansson SL., Lin MF., and Batra SK. Aberrant expression of transmembrane mucins, MUC1 and MUC4 in human prostate carcinomas and cell lines *The Prostate* 1;65 (17):7840-6 2006.
95. Jain M., Chauhan SC., Singh AP., Venketraman G., Colcher D. and Batra SK. Penetratin improves tumor retention of single-chain antibodies: A novel step towards optimization of radioimmunotherapy of solid tumors. *Cancer Research* Sep 1;65 (17):7840-6 2005.
96. Chauhan SC., Jain M., Moore E.D., Wittel UA., Li J., Gwilt PR., Colcher D. and Batra SK. Pharmacokinetic and biodistribution of ¹⁷⁷Lu-labeled multivalent single chain Fv construct of monoclonal antibody CC49 *European J. Nuclear Medicine and Mol Imaging* 32: 264-73 2005.
97. Wittel UA., Jain M., Goel A., Chauhan SC. and Batra SK. The *in vivo* characteristics of genetically engineered divalent and tetravalent single chain antibody constructs. *J. Nuclear Medicine and Biology* 32: 157-64 2005.
98. Wittel UA., Jain M., Goel A., Baranowska-Kortylewicz J., Kurizaki T., Chauhan SC., Agrawal DK., Colcher D., and Batra, SK. Engineering and characterization of a divalent single-chain Fv angiotensin II fusion construct of monoclonal antibody CC49. *Biochem Biophys Res Commun.* 329(1):168-76 2005.
99. Moniaux, N., Varshney GC., Chauhan, SC., Copin, MC., Jain, M., Wittel, UA., Andrianifahanana, M., Aubert, JP., and Batra, SK. Generation and characterization of anti-MUC4 monoclonal

antibodies reactive with normal and cancer cells in humans. *J Histochem Cytochem.* 52(2):253-61. 2004.

100. Singh, A.P., Moniaux, N., **Chauhan, SC.**, Meza JL. and Batra SK. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. *Cancer Research* 64:622-630 2004.
101. Batra SK., Jain M., Wittel UA., **Chauhan SC.** and Colcher D. Pharmacokinetics and biodistribution of genetically engineered antibodies. *Curr Opin Biotechnol.* 13(6):603-8 2002.
102. Standop J., Schneider MB., Ulrich A., **Chauhan SC.**, Moniaux N., Bichler MW., Batra SK. and Pour PM. The pattern of xenobiotic-metabolizing enzymes in the human pancreas. *J. Toxicol. Environ. Health*, 65(19):1379-400, 2002
103. Naz RK. and **Chauhan SC.** Human sperm-specific Peptide vaccine that causes long-term reversible contraception. *Biol Reprod.* 67(2):674-80 2002
104. **Chauhan SC.** and Naz RK. Effect of antibodies to sperm specific recombinant contraceptive vaccinogen (rCV) on murine fertilization: Search for an animal model to examine its contraceptive potential. *Molecular Reproduction and Development* 60(3):425-32 2001.
105. Naz RK., **Chauhan SC.** and Trivedi RN. Monoclonal antibodies against human sperm- specific YLP12 peptide sequence involved in oocyte binding. *Arch Androl.* 48(3):169-75 2002.
106. Naz RK. and **Chauhan SC.** Presence of YLP12 synthetic peptide in sera and seminal plasma of Immunoinfertile men. *Molecular Human Reproduction* 7(1): 21-26 2001.
107. Naz RK., **Chauhan, SC.** and Rose L. Expression of alpha and gamma interferon receptors in the sperm cell *Molecular Reproduction and Development* 54(2):189-197 2000.
108. Basnode FW., **Chauhan SC.**, Makker A. and Singh MM. Uterine luminal epithelial alkaline phosphatase activity and pinopod development in relation to endometrial sensitivity in rat. *Contraception* 58(1) 61-68 1998.
109. Singh MM., **Chauhan SC.**, Maitra SC., Trivedi RN. and Kamboj VP. Correlation of pinopod development on uterine luminal epithelial surface with hormonal events and endometrial sensitivity in rat. *Eur.J. Endocrinology* 135, 107-117 1996.
110. Singh MM., Trivedi RN., **Chauhan SC.**, Srivastava VML. and Kamboj VP. Uterine estradiol and progesterone receptor concentration, activities of certain antioxidant enzymes and dehydrogenases and histoarchitecture in relation to time of secretion of nidatory estrogen and high endometrial sensitivity in rat. *J Steroid Biochem Mol Biol* 59(4) 215-224 1996.
111. **Chauhan SC.**, Singh MM., Maitra SC. and Kamboj VP. Inhibition of progesterone induced development of giant mitochondria in uterine glandular epithelial cells by an antiestrogen in rat. *Contraception* 54, 259-264, 1996.
112. Trivedi RN., **Chauhan SC.**, Dwivedi A., Maitra SC., Kamboj VP. and Singh MM. Time related effects of a triphenylethylene antiestrogen on estrogen induced changes in uterine weight, estrogen receptors and endometrial sensitivity in immature rats. *Contraception* 51, 367-379, 1995.
113. Saxena AK., Arya S., Singh SK. and **Chauhan SC.** SEM studies on the microtopography of eggs of poultry shaft louse, Menopon gallinae. (Pthiroptera:Amblycera). *Rivista di Parasitologia* XI(LV)N2, 275-281,1994
114. **Chauhan SC.** and Ahmad M. Plant parasitic and soil nematodes infesting leguminous crops in Rishikesh and Haridwar regions (U. P.). *J Nat. & Physical Sciences* 4,179-186, 1990.

OTHER PUBLICATIONS:

Radio Interview:

Subhash Chauhan

South Dakota Public Broadcasting

Title: Cervical Cancer in American Indian Women

Date: 08-24-2012

TV Interview:

Subhash Chauhan

Keloland TV, Sioux Falls. South Dakota

Title: Sanford Research 2012 progress and future prospects

Date: 12-24-2012

<http://www.keloland.com/videoarchive/index.cfm?VideoFile=121223insidekeloland>

1: Massey AE, Sikander M, Chauhan N, Kumari S, Setua S, Shetty AB, Mandil H, Kashyap VK, Khan S, Jaggi M, Yallapu MM, Hafeez BB, Chauhan SC. Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. *Nanomedicine*. 2019 Jun 4;102027. doi: 10.1016/j.nano.2019.102027. PMID: 31170509.

2: Khan S, Setua S, Kumari S, Dan N, Massey A, Hafeez BB, Yallapu MM, Stiles ZE, Alabkaa A, Yue J, Ganju A, Behrman S, Jaggi M, Chauhan SC. Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. *Biomaterials*. 2019 Jul;208:83-97. doi:10.1016/j.biomaterials.2019.04.005. Epub 2019 Apr 8. PubMed PMID: 30999154.

3: Sikander M, Malik S, Chauhan N, Khan P, Kumari S, Kashyap VK, Khan S, Ganju A, Halaweish FT, Yallapu MM, Jaggi M, Chauhan SC. Cucurbitacin D Reprograms Glucose Metabolic Network in Prostate Cancer. *Cancers (Basel)*. 2019 Mar 14;11(3). pii:E364. doi: 10.3390/cancers11030364. PubMed PMID: 30875788; PubMed Central PMCID: PMC6469021.

4: Romero LO, Massey AE, Mata-Daboin AD, Sierra-Valdez FJ, Chauhan SC, Cordero-Morales JF, Vásquez V. Dietary fatty acids fine-tune Piezo1 mechanical response. *Nat Commun*. 2019 Mar 13;10(1):1200. doi: 10.1038/s41467-019-09055-7. PubMed PMID: 30867417; PubMed Central PMCID: PMC6416271.

News Interview

Subhash Chauhan

Published in Indian Country Today Media Network

Title: Sanford Health Researching Cervical Cancer in Native American Women

<http://indiancountrytodaymedianetwork.com/2012/09/12/sanford-health-researching-cervical-cancer-in-native-american-women-132928#ixzz26I1tyiGx>

Date: 09-12-2012

RECENT PRESENTATIONS:

1. **Stiles ZE**, Khan S, Patton KT, Behrman SW, Chauhan SC. *Transmembrane Mucin MUC13 Distinguishes Intraductal Papillary Mucinous Neoplasms from Non-Mucinous Cysts and is Associated With High-Risk Lesions*. *Mini-oral presentation at Americas Hepato-Pancreato-Biliary Association (AHPBA) 2018 Annual Meeting, Miami, FL. March 9th, 2018.
2. **Stiles ZE**, Khan S, Patton KT, Behrman SW, Chauhan SC. *MUC13 Distinguishes IPMNs from Non-Mucinous Lesions and is Associated With High-Risk Features*. *To be presented as a long-oral podium presentation at The Pancreas Club 2018 Annual Meeting, Washington D.C. June 2nd, 2018.
3. 679 / 2 - ABI-231: A novel small molecule suppresses tumor growth and metastatic phenotypes of cervical cancer cells via targeting HPV E6 and E7, V. K. Kashyap, B. B. Hafeez, Q. Wang, N. Chauhan, P. K. B. Nagesh, N. Dan, s. kumari, S. Malik, S. Setua, A. Ganju, M. M. Yallapu, D. D. Miller, W. Li, M. Jaggi, S. C. Chauhan, April 15, 2018, 1:00 PM - 5:00 PM, AACR 2018, Chicago, Illinois.
4. LB-011 / 11 - Novel nano-formulation of paclitaxel for pancreatic cancer therapy, B. B. Hafeez, A. E. Massey, V. K. Kashyap, M. Sikander, A. Shetty, M. Chaib, H. Mandil, M. Yallapu, M. Jaggi, S. C. Chauhan, April 15, 2018, 1:00 PM - 5:00 PM, AACR 2018, Chicago, Illinois.
5. 198 / 28 - MUC13 promotes pancreatic tumor-stromal interactions by influencing tumor microenvironment, S. S. Khan, K. Doxtater, S. Kumari, S. Setua, M. Sikander, S. Malik, M. M. Yallapu, S. W. Behrman, S. C. Chauhan, M. Jaggi, April 15, 2018, 1:00 PM - 5:00 PM, AACR 2018, Chicago, Illinois.
6. 1449 / 19 - Aberrant expression of protein kinase D1 influences metabolic reconditioning in pancreatic cancer, S. Kumari, S. Khan, M. M. Yallapu, S. C. Chauhan, M. Jaggi; April 16, 2018, 8:00 AM - 12:00 PM, AACR 2018, Chicago, Illinois.
7. 2110 / 25 - Therapeutic intervention for pancreatic cancer using autologous exosomes, S. Setua, S. Khan, M. Yallapu, S. Kumari, M. Jaggi, S. C. Chauhan; April 16, 2018, 1:00 PM - 5:00 PM, Chicago, Illinois.
8. 4657 / 20 - Docetaxel nanoformulation reverts drug resistance in prostate cancer, P. B. Nagesh, P. Chowdhury, E. Hatami, V. K. Kashyap, B. B. Hafeez, S. Khan, S. C. Chauhan, M. Jaggi, M. Yallapu, April 17, 2018, 1:00 PM - 5:00 PM, AACR 2018, Chicago, Illinois.
9. LB-400 / 28 - Tannic acid induces prostate cancer cell death via unfolded protein response (UPR) and modulation of CHOP, E. Hatami, P. Bhusetty Nagesh, P. Chowdhury, V. K. Kashyap, S. Khan, B. Hafeez, M. Jaggi, S. C. Chauhan, M. Yallapu; April 18, 2018, 8:00 AM - 12:00 PM, AACR 2018, Chicago, Illinois.
10. 5777 / 3 - Ormeloxifene augments the therapeutic response of enzalutamide via targeting androgen receptor splice variant 7, B. B. Hafeez, A. E. Massey, V. K. Kashyap, M. Sikander, A. Shetty, M. Chaib, H. Mandil, S. Malik, M. M. Yallapu, M. Jaggi, S. C. Chauhan; April 18, 2018, 8:00 AM - 12:00 PM AACR 2018, Chicago, Illinois.
11. 2934 / 14 - Cucurbitacin D enhances the therapeutic efficacy of docetaxel via targeting cancer stem cells and miR-145, M. Sikander, S. Malik, B. B. Hafeez, H. Mandil, F. T. Halaweish, M. Jaggi, S. C. Chauhan; April 16, 2018, 1:00 PM - 5:00 PM, AACR 2018, Chicago, Illinois.
12. 5178 / 10 - MUC13 is a novel molecular signature, for early detection and metastatic colorectal cancer, M. K. Tripathi, C. Zacheaus, K. Doxtater, Z. Stiles, F. Keramatnia, N. Zafar, M. Amin, M. Jaggi, S. Chauhan, April

- 18, 2018, 8:00 AM - 12:00 PM, AACR 2018, Chicago, Illinois.
13. 5138 / 19 - Comparative profiling for bacterial inhabitation in pancreatic ductal adenocarcinoma and matched adjacent normal tissues, S. S. Khan, P. Banerjee, S. Setua, D. Higgins, S. Kedia, Y. Jiang, M. Jaggi, S. Chauhan, April 18, 2018, 8:00 AM - 12:00 PM, AACR 2018, Chicago, Illinois.
 14. M4065 - Docetaxel Loaded Magnetic Nanoparticles for Overcoming Drug Resistance in Prostate Cancer, Pallabita Chowdhury, Prashanth Kumar Nagesh, Elham Hatami, Sheema Khan, Subhash Chauhan, Meena Jaggi, Murali Yallapu, November 13 – Monday Time: 12:00 pm - 01:00 pm, AAPS 2017, San Diego.
 15. W1020 - Physico-Chemical and Biological Interactions of Protein Corona of Human Lung Fluid with Tannic Acid Nanoformulation, Elham Hatami, Pallabita Chowdhury, Prashanth Bhusetty, Subhash Chauhan, Meena Jaggi, Murali Yallapu, 9:00 AM–10:00 AM Nov 15, 2017, AAPS 2017, San Diego.
 16. M7068 - Self- Targeting Nanoparticles as a Potential Therapeutic Model for Targeting Cancer, Pallabita Chowdhury, Elham Hatami, Prashanth Kumar Nagesh, Sheema Khan, Subhash Chauhan, Meena Jaggi, Murali Yallapu, 3:00 PM–4:00 PM Nov 13, 2017, AAPS 2017, San Diego.
 17. M5029 - Mir-145 Mediated TRAIL Sensitization In Pancreatic Cancer: Novel Combined Treatment Strategy, Saini Setua, Sheema Khan, Murali Yallapu, Stephen Behrman, Meena Jaggi, Subhash Chauhan, Poster Forum 2 - Monday - 01:00 pm, AAPS 2017, San Diego.
 18. M7015 - Therapeutic Perspectives of Tannic Acid in Inducing ER Stress Mediated Unfolded Protein Response (UPR) in Prostate Cancer Cell Death, Prashanth Kumar Bhusetty Nagesh, Pallabita Chowdhury, Vivek Kumar Kashyap, Elham Hatami, Sheema Khan, Bilal Hafeez, Meena Jaggi, Subhash Chauhan, Murali Yallapu, Poster Forum 2 - Monday - 03:00 pm, AAPS 2017, San Diego.
 19. W1128 - ABI-231: A novel microtubule inhibitor suppresses tumor growth and metastatic phenotypes of cervical cancer cells via targeting HPV E6 and E7, Vivek Kashyap, Bilal Hafeez, Qinghai Wang, Neeraj Chauhan, Prashanth K B Nagesh, Nirnoy Dan, Shabnam Malik, Saini Setua, Aditya Ganju, Murali Yallapu, Duane Miller, Wei Li, Meena Jaggi, Subhash Chauhan, Poster Forum 6 - Wednesday - 09:00 am, AAPS 2017, San Diego.
 20. Efficacy of Different Chitosan Nanoparticle Combinations in Inhibiting Growth of Two Strains of: PR71 Enterococcus Faecalis: PR71, M. James; P. Chowdhury; M. Yallapu; A. Lloyd; J. O'Dell; J. Babu; F. Garcia-Godoy; S. Chauhan; G. Huang; M. Marchesan, Journal of Endodontics. 44(3):e37, MAR 2018,
 21. Partial wave spectroscopy based nanoscale structural disorder analysis for cancer diagnosis and treatment, Almadadi, Huda; Sahay, Peeyush; Nagesh, Prashanth K. B.; Yallapu, Murali M.; Jaggi, Meena; Chauhan, Subhash C.; Pradhan, Prabhakar, APS March Meeting 2017, abstract id. Y6.008
 22. MUC13 PEPTIDE MODULATES TME OF PANCREATIC CANCER BY INDUCTION OF TAMs AND ACTIVATION OF CAFs: Mehdi Chaib, Advait Shetty, Andrew Massey, Sonam Kumari, Vivek Kashyab, Manish Tripathi, Bilal Hafeez, Meena Jaggi, Subhash C. Chauhan, April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.
 23. DOCETAXEL LOADED MAGNETIC NANOPARTICLES FOR OVERCOMING DRUG RESISTANCE IN PROSTATE CANCER: Pallabita Chowdhury, Prashanth K.B. Nagesh, Elham Hatami, Sheema Khan, Subhash C. Chauhan, Meena Jaggi, Murali M. Yallapu April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.
 24. TARGETED DRUG DELIVERY USING NOVEL ANTI_MUC12 CONJUGATED NANOPARTICLES FOR PANCREATIC CANCER: Nirnoy Dan, Saini Setua, Sheema Khan, Murali M. Yallapu, Meena Jaggi, Subhash C. Chauhan April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.
 25. TANNIC ACID INDUCES ENDOPLASMIC RETICULUM STRESS-MEDIATED APOPTOSIS IN PROSTATE CANCER: Elham Hatami, Prashanth K.B. Nagesh, Pallabita Chowdhury, Vivek Kashyab, Sheema Khan, Bilal Hafeez, Subhash C. Chauhan, Meena Jaggi, Murali M. Yallapu, April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.

26. ABERRANT EXPRESSION OF PROTEIN KINASE D1 INFLUENCES METABOLIC RECONDITIONING IN PANCREATIC CANCER: Sonam Kumari, Sheema Khan, Murali M. Yallapu, Subhash C. Chauhan, Meena Jaggi
April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.
27. ASSESMENT OF PHYSICAL CHARACTERISTICS OF CANCER CELLS AND NANOPARTICLES BY ATOMIC FORCE MICROSCOPY: Andrew Massey, April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.
28. TARGETING MUC12 TO IMPROVE SURVIVAL IN PATIENTS WHO SMOKE AND DRINK: Kamalika Samanta, Sheema Khan, Saini Setua, Sonam Kumari, Nirnoy Dan, Kyle Doxtater, Pragathi Reddy Gunnam, Murali M. Yallapu, Meena Jaggi, Subhash C. Chauhan,
April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA.
29. THERAPEUTIC INTERVENTION FOR PANCREATIC CANCER USING AUTOLOGOUS EXOSOMES: Saini Setua, Sheema Khan, Andrew Massey, Murali M. Yallapu, Meena Jaggi, Subhash C. Chauhan,
April 20th, 2018, 1:00-3:00 PM, Graduate Research Day, University of Tennessee Health Science Center, Memphis, TN, USA
30. Sheema Khan, Stephen W Behrman, Nadeem Zafar, Meena Jaggi, **Subhash C. Chauhan**. MUC13- An early diagnostic marker for pancreatic ductal adenocarcinoma. SSAT, 57th Annual Meeting May 21-24, 2016, San Diego California. San Diego California. 50th Annual Pancreas Club Meeting May 20-21, 2016, San Diego California.
31. Saini Setua, MS, Sheema Khan, Murali M Yallapu, Stephen W Behrman, Meena Jaggi, **Subhash C. Chauhan**. Restitution of tumor suppressor mir-145 using magnetic nanoparticles inhibits pancreatic cancer. *Invited Oral Talk*; 50th Annual Pancreas Club Meeting May 20-21, 2016, San Diego California. SSAT, 57th Annual Meeting May 21-24, 2016, San Diego California.
32. Stephen W Behrman, Sheema Khan, Nadeem Zafar, Meena Jaggi, **Subhash C. Chauhan**. MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression. SSAT, 57th Annual Meeting May 21-24, 2016, San Diego California. 50th Annual Pancreas Club Meeting May 20-21, 2016, San Diego California.
33. Saini Setua, Sheema Khan, Murali M. Yallapu, Stephen W. Behrman, Nadeem Zafar, Meena Jaggi, Subhash C. Chauhan. Targeting MUC13 to Overcome the Survival Mechanisms for Improved Response to Chemotherapy. *AACR Annual Meeting 2017*, April 1 – 5, 2017, Washington, D.C.
34. Saini Setua, Sheema Khan, Murali M. Yallapu, Mohammed Sikander, Meena Jaggi, **Subhash C. Chauhan**. Development of a microRNA-145 magnetic nanoformulation for pancreatic cancer therapy. *AAPS Annual Meeting 2016*, November 13-17, 2016, Colorado, Denver.
35. Saini Setua, Sheema Khan, Murali M. Yallapu, Meena Jaggi, **Subhash C. Chauhan**. MicroRNA-145 overcomes chemo-resistance in pancreatic cancer leading to combined treatment interventions. *Graduate research day, 2016*. University of Tennessee Health Science Center, USA.
36. Saini Setua, Sheema Khan, Murali M. Yallapu, Meena Jaggi, **Subhash C. Chauhan**.
37. MUC13 is involved in TRAIL resistance in pancreatic cancer. *Graduate research day, 2017*. University of Tennessee Health Science Center, USA.
38. Saini Setua, Sheema Khan, Kyle Doxtater, Murali M. Yallapu, Meena Jaggi, and **Subhash C. Chauhan**. miR-145: Revival of a Dragon in Pancreatic Cancer. *Journal of Nature and Science (JNSCI)*, 3(3):e332, 2017
39. Saini Setua, Saini Setua, Meena Jaggi, Murali M. Yallapu, **Subhash C. Chauhan**. Multifunctional magnetic nanoparticles for cancer treatment. *Nanotechnologies in Preventive and Regenerative Medicine*. Elsevier Book chapter.[Epub ahead of print].

40. Bilal B Hafeez, Vivek K Kashyap, Vijayakumar N Boya, Aditya Ganju, Mohammad Sikander, Murali M Yallapu, Meena Jaggi, **Subhash C. Chauhan**. Novel nanoparticle formulation of Plumbagin for pancreatic cancer treatment. *AAPS Annual Meeting 2016*, November 13-17, 2016, Colorado, Denver.
41. Mohammed Sikander, Bilal Bin Hafeez, Shabnam Malik, Aditya Ganju, Fathi T. Halaweish², Murali Mohan Yallapu, Subhash C. Chauhan, Meena Jaggi. Cucurbitacin D inhibits prostate tumor growth via targeting glucose metabolism. *AACR Annual Meeting 2017*, April 1 – 5, 2017, Washington, D.C.
42. Nirnoy Dan, Saini Setua, Sheema Khan, Murali M. Yallapu, Meena Jaggi, **Subhash C. Chauhan**. Targeted drug delivery using a novel anti-MUC13 conjugated nanoparticles for pancreatic cancer. *Graduate research day, 2017*. University of Tennessee Health Science Center, USA.
43. Kyle Doxtater, Sheema Khan, Sonam Kumari, Saini Setua, Mohammad Sikander, Shabnam Malik, Murali M. Yallapu, **Subhash C. Chauhan**, Meena Jaggi. MUC13 promotes pancreatic tumor-stromal interactions by influencing tumor microenvironment. *Graduate research day, 2017*. University of Tennessee Health Science Center, USA.
44. Sonam Kumari, Sheema Khan, Subash C. Gupta, Vivek K. Kashyap Murali M. Yallapu, **Subhash C. Chauhan**, Meena Jaggi. MUC13 induced NF κ B activation regulates metabolic reprogramming by promoting crosstalk with GLUT-1 receptor. *AACR Annual Meeting 2017*, April 1 – 5, 2017, Washington, D.C.
45. Sonam Kumari, Sheema Khan, Subash C. Gupta, Vivek K. Kashyap Murali M. Yallapu, **Subhash C. Chauhan**, Meena Jaggi. MUC13 induced NF κ B activation regulates metabolic reprogramming by promoting crosstalk with GLUT-1. *Graduate research day, 2017*. University of Tennessee Health Science Center, USA.
46. Vivek K Kashyap, Bilal B. Hafeez., Qinghui Wang, Saini Setua, Aditya Ganju, Murali M. Yallapu, Duane D. Miller, Wei Li , Meena Jaggi, **Subhash C. Chauhan**. Attenuation of pancreatic tumor growth by a small molecule tubulin inhibitor. *AACR Annual Meeting 2017*, April 1 – 5, 2017, Washington, D.C.
47. V. K. Kashyap, Q. Wang, B. B. Hafeez, A. K. Ganju, M. M. Yallapu, D. Miller, L. Wei, M. Jaggi, **S. C. Chauhan**. ABI-231 Inhibits the Growth of Pancreatic Cancer Cells In Vitro and In Vivo via Targeting BetaTubulin. . *AAPS Annual Meeting 2016*, November 13-17, 2016, Colorado, Denver.
48. Aditya Ganju, Bilal B. Hafeez, Mohammad Sikander, Vivek K Kashyap, Murali M. Yallapu, **Subhash C. Chauhan**, Meena Jaggi. Ormeloxifene suppress the growth of prostate tumor via inhibition of β -catenin induced AR signaling. *AACR Annual Meeting 2017*, April 1 – 5, 2017, Washington, D.C.
49. Aditya Ganju, Bilal Bin Hafeez, Fathi Halaweish, Wei Li, Man Mohan Singh, Murali Mohan Yallapu, Subhash Chauhan, **Meena Jaggi**. Ormeloxifene, a novel pharmacological activator of PKD1 enhances docetaxel sensitivity in prostate cancer. Abstract Number 3862, Poster Session 19, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA*.
50. Sonam Kumari, Sheema Khan, Subhash Chauhan, **Meena Jaggi**. Role of MUC13 as non-hypoxic stimuli inducing HIF-1 α in pancreatic cancer under normoxia. Abstract Number 51, Poster Session 2, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA*.
51. Sheema Khan, Mara C. Ebeling, Mohammad Sikander, Aditya Ganju, Murali M. Yallapu, Tomoko Ise, Satoshi Nagata, Stephen W. Behrman, Nadeem Zafar, Jim Y. Wan, Hemendra M. Ghimire, Peeyush Sahay, Prabhakar Pradhan, **Meena Jaggi**, Subhash C. Chauhan. MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression. Abstract

- Number 4592, Poster Session 8, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA.*
52. Mohammed Sikander, Bilal Bin Hafeez, Fathi T. Halaweish, Murali M. Yallapu, **Meena Jaggi**, Subhash C. Chauhan. Novel cucurbitacin analogue Cuc D exhibits potent anti-cancer activity in cervical cancer. Abstract Number 3081, Poster Session 19, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA.*
 53. Vivek K. Kashyap, Sheema Khan, Mohammad Sikander, Diane M. Maher, Santosh Kumar, Namita Sinha, Murali M. Yallapu, Nadeem Zafar, **Meena Jaggi**, Subhash C. Chauhan. Comorbidity factors associated with human papillomavirus infectivity: Implications in cervical cancer health disparity. Abstract Number 1745, Poster Session 35, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA.*
 54. Saini Setua, Sheema Khan, Murali Mohan Yallapu, Mohammed Sikander, Stephen W. Behrman, **Meena Jaggi**, Subhash C. Chauhan. Mir-145 based magnetic nanoformulation for pancreatic cancer therapy. Abstract Number 1071, Poster Session 6, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA.*
 55. Prashanth Kumar Bhusetty Nagesh, Nia Johnson, Vijaya K.N. Boya, Pallabita Chowdhury, Aditya Ganju, Bilal Hafeez, Sheema Khan, **Meena Jaggi**, Subhash C. Chauhan, Murali M. Yallapu. PSMA antibody functionalized docetaxel-loaded magnetic nanoparticles for prostate cancer therapy. Abstract Number 1312, Poster Session 19, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA.*
 56. Vijayakumar N. Boya, Renn Lovett, Saini Satua, Vaibhav Gandhi, Prashanth K.B. Nagesh, **Meena Jaggi**, Subhash C. Chauhan, Murali M. Yallapu. Mucopenetrating magnetic nanoparticles for drug delivery. Abstract Number 2197, Poster Session 20, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA.*
 57. Bilal B. Hafeez, Vivek K. Kashyap, Vijayakumar N. Boya, Aditya Ganju, Mohammad Sikander, Murali M. Yallapu, **Meena Jaggi**, Subhash C. Chauhan. Novel nanoparticle formulation of Plumbagin for pancreatic cancer treatment. Abstract Number 2208, Poster Session 20, *American Association of Cancer Research (AACR) Annual Meeting 2016 (April 16-20), New Orleans, LA.*
 58. Saini Setua, Stephen Behrman, Sheema Khan, Murali M. Yallapu, Meena Jaggi, **Subhash C. Chauhan**. Restitution of tumor suppressor mIR-145 using magnetic nanoparticles inhibits pancreatic cancer. **50th Annual Pancreas Club Meeting May 20-21, 2016, the Hyatt Regency Mission Bay, San Diego California**
 59. Sheema Khan, Stephen Behrman, Nadeem Zafar, Meena Jaggi, **Subhash C. Chauhan**. MUC13- An Early Diagnostic Marker for Pancreatic Ductal Adenocarcinoma. **50th Annual Pancreas Club Meeting May 20-21, 2016, the Hyatt Regency Mission Bay, San Diego California**
 60. Sheema Khan, Stephen Behrman, Nadeem Zafar, Meena Jaggi, **Subhash C. Chauhan**. MUC13 Interaction with Receptor Tyrosine Kinase HER2 Drives Pancreatic Ductal Adenocarcinoma Progression. **50th Annual Pancreas Club Meeting May 20-21, 2016, the Hyatt Regency Mission Bay, San Diego California**
 61. Saini Setua, Stephen Behrman, Sheema Khan, Murali M. Yallapu, Meena Jaggi, **Subhash C. Chauhan**. Restitution of tumor suppressor mIR-145 using magnetic nanoparticles inhibits pancreatic cancer. **Digestive Disease Week (DDW), May 21-24, 2016, Convention Center, San Diego, California**

62. Sheema Khan, Stephen Behrman, Nadeem Zafar, Meena Jaggi, **Subhash C. Chauhan**. MUC13- An Early Diagnostic Marker for Pancreatic Ductal Adenocarcinoma. **Digestive Disease Week (DDW), May 21-24, 2016, Convention Center, San Diego, California**
63. Sheema Khan, Stephen Behrman, Nadeem Zafar, Meena Jaggi, **Subhash C. Chauhan**. MUC13 Interaction with Receptor Tyrosine Kinase HER2 Drives Pancreatic Ductal Adenocarcinoma Progression. **Digestive Disease Week (DDW), May 21-24, 2016, Convention Center, San Diego, California**
64. Mohd Saif Zaman, Neeraj Chauhan, Rishi K. Gara, Diane Maher, Sonam Kumari, Mohammed Sikander, Sheema Khan, Murali M. Yallapu, Meena Jaggi, **Subhash C. Chauhan**. Smoking Carcinogen (BaP) enhances tumorigenic phenotypes of cervical cancer cells by modulation of HPV oncogenes and microRNA profiles, 182 Poster Session, [106 American Association of Cancer Research \(AACR\) Annual Meeting 2015 \(April 18-22\), Philadelphia, PA.](#)
65. Rishi K. Gara, Sonam Kumari, Sheema Khan, Neeraj Chauhan, Aditya Ganju, **Subhash C. Chauhan**, Meena Jaggi. Protein Kinase D1 induces autophagic cell death through activation of endoplasmic reticulum stress in prostate cancer cells, 1001 Poster Session, [106 American Association of Cancer Research \(AACR\) Annual Meeting 2015 \(April 18-22\), Philadelphia, PA.](#)
66. Aditya Ganju, Rishi Gara, Sonam Kumari, Man Mohan Singh, **Subhash C. Chauhan**, Meena Jaggi. Ormeloxifene attenuates wnt/ β -catenin signaling in colon cancer cells by modulation of PKD1 and glycolytic pathways 2072 Poster Session, [106 American Association of Cancer Research \(AACR\) Annual Meeting 2015 \(April 18-22\), Philadelphia, PA.](#)
67. Sheema Khan, Murali M. Yallapu, Sonam Kumari, Aditya Ganju, Swathi Balakrishna, Stephen W. Behrman, Nadeem Zafar, Meena Jaggi, **Subhash C. Chauhan**. Attenuation of pancreatic cancer stemness and growth by a novel magnetic nanoparticle formulation, 3676 Poster Session, [106 American Association of Cancer Research \(AACR\) Annual Meeting 2015 \(April 18-22\), Philadelphia, PA.](#)
68. Sheema Khan, Neeraj Chauhan, Murali M. Yallapu, Mara C. Ebeling, Swathi Balakrishna, Robert T. Ellis, Paul A. Thompson, Stephen W. Behrman, Nadeem Zafar, Man M. Singh, Fathi T. Halaweish, Meena Jaggi, **Subhash C. Chauhan**. Generation of a novel ormeloxifene nanoparticle formulation for pancreatic cancer treatment, 4392 Poster Session. [106 American Association of Cancer Research \(AACR\) Annual Meeting 2015 \(April 18-22\), Philadelphia, PA.](#)
69. Mohammed Sikander, Sheema Khan, Neeraj Chauhan, Mohd Saif Zaman, Murali Mohan Yallapu, Fathi T. Halaweish, Bhavin Chauhan, Shabnam Malik, Meena Jaggi, **Subhash C. Chauhan**. Anticancer activity of novel cucurbitacin analogue in pancreatic cancer, 4468 Poster Session, [106 American Association of Cancer Research \(AACR\) Annual Meeting 2015 \(April 18-22\), Philadelphia, PA.](#)
70. Murali M. Yallapu, Neeraj Chauhan, Sheema Khan, Meena Jaggi, Aditya Ganju, Diane M. Maher, Mara C. Ebeling, **Subhash C. Chauhan**. Novel pluronic F127-coated paclitaxel nanoparticles formulation for pancreatic cancer. 5534 Poster Session, [106 American Association of Cancer Research \(AACR\) Annual Meeting 2015 \(April 18-22\), Philadelphia, PA.](#)
71. Zafar Nadeem, Khan Sheema, Behrman Stephen W, Jaggi Meena and **Chauhan Subhash**. Suppression of Pancreatic Ductal Carcinoma Growth and Invasion By Targeting MUC13 Mucin Through MicroRNA-145- A Tumor Heterograft Study in Mice (Abstract 2467). **2015 United States & Canadian Academy of Pathology Annual Meeting (USCAP), March 23-27 2015, Boston, MA.**

72. Behrman Stephen W, Zafar Nadeem, Khan Sheema, Jaggi Meena and **Chauhan Subhash**. Surgical management of complicated pancreatic pseudocysts following acute pancreatitis. **49th Annual Pancreas Club meeting**, May 15-16, 2015, Washington, DC.
73. Gara RK, Kumari S, Ganju A, Yallapu MM, Shah A, Khan S, Singh MM, **Chauhan SC** and **Jaggi M**. Induction of Autophagy by ormeloxifene and mevastatin through protein kinase D1 in prostate cancer cells. *105 American Association of Cancer Research (AACR) Annual Meeting 2014 (April 5-9), San Diego CA.*
74. Sikander M, Zaman MS, Chauhan N, Yallapu MM, Khan S, Halaweish FT, Chauhan B, Kumari S, **Jaggi M** and **Chauhan SC**. A multi-targeted approach for pancreatic cancer treatment by a novel cucurbitacin analogue. *105 American Association of Cancer Research (AACR) Annual Meeting 2014 (April 5-9), San Diego CA.*
75. Yallapu MM, Chauhan N, Othman SF, Khalilzad-Sharghi V, Jaggi M and **Chauhan SC**. Characterization of a novel magnetic nanoparticles formulation for cancer therapeutic applications. *105 American Association of Cancer Research (AACR) Annual Meeting 2014 (April 5-9), San Diego CA.*
76. Chauhan N, Zaman MS, Maher DM, Ebeling MC, Yallapu MM, Jaggi M and **Chauhan SC**. Ormeloxifene inhibits cervical cancer cell growth through intrinsic apoptotic pathway. *105 American Association of Cancer Research (AACR) Annual Meeting 2014 (April 5-9), San Diego CA.*
77. Ganju A, Sundram V, Miskimins K, Gara R, Khan S, Singh MM, **Chauhan SC** and Jaggi M. Ormeloxifene attenuates metastatic and glycolytic pathways in breast cancer cells. *105 American Association of Cancer Research (AACR) Annual Meeting 2014 (April 5-9), San Diego CA.*
78. Khan S, Ebeling M, Ansarullah, Chauhan N, Gara R, Jaggi M, Zhao H, **Chauhan SC**. Approach to enhance delivery and sensitivity of gemcitabine in pancreatic cancer by suppression of desmoplasia. *105 American Association of Cancer Research (AACR) Annual Meeting 2014 (April 5-9), San Diego CA.*
79. Zaman MS, Chauhan N, Maher DM, Yallapu MM, Jaggi M and **Chauhan SC**. Curcumin nanoformulation. A new therapeutic approach for cervical cancer treatment. *105 American Association of Cancer Research (AACR) Annual Meeting 2014 (April 5-9), San Diego CA.*
80. Onishi, C., Kopel L. C., Halaweish, F. T., **Chauhan, S.C.** Drug Design and Molecular Modeling of Ormeloxifene Analogs Targeting Ovarian Cancer: *48th ACS Midwest Regional Meeting 2013* (Oct 16-19), Springfield, Missouri.
81. Yallapu MM., Ebleling MC., Khan S., Chauhan N., Gupta BK., Sundram V., Jaggi M. and **Chauhan SC**. Novel curcumin loaded magnetic nanoparticles for pancreatic cancer treatment. *104 American Association of Cancer Research (AACR) Annual Meeting 2013 (April 6-10), Washington DC.*
82. Khan S., Maher D., Ebleling MC., Kumar D., Jaggi M. and **Chauhan SC**. MicroRNA-145 targets MUC13 and suppresses invasion and metastasis of pancreatic cancer cells. *104 American Association of Cancer Research (AACR) Annual Meeting 2013 (April 6-10), Washington DC.*
83. Maher D., Bell M., Schaefer A., Jaggi M. and **Chauhan SC**. Benzo(a)pyrene exposure increases expression of HPV oncoproteins: a potential co-factor for increased cervical cancer among Northern

- Plains American Indian women. *104 American Association of Cancer Research (AACR) Annual Meeting 2013 (April 6-10), Washington DC.*
84. Sundram V., Gara R., Singh MM., **Chauhan SC** and Jaggi M. Ormeloxifene modulates beta-catenin/TCF pathway in colon cancer. *104 American Association of Cancer Research (AACR) Annual Meeting 2013 (April 6-10), Washington DC.*
 85. Sundram V., Radel S., Hughes J., Singh MM., **Chauhan SC.** and Jaggi M. Suppression of prostate cancer growth and invasion by a triphenyl ethylene compound ormeloxifene. *103 American Association of Cancer Research (AACR) Annual Meeting 2012, Chicago, IL.*
 86. Yallapu MM., Othman SF., Curtis ET., Chauhan N., Bauer NA., Jaggi M. and **Chauhan SC.** Curcumin loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. *103 American Association of Cancer Research (AACR) Annual Meeting 2012, Chicago, IL.*
 87. Chauhan N., Maher DM., Yallapu MM., Ebeling MC., Jaggi M. and **Chauhan SC.** Therapeutic effects of ormeloxifene on cervical cancer. *103 American Association of Cancer Research (AACR) Annual Meeting 2012, Chicago, IL.*
 88. Maher DM., Stephenson P., Gupta BK., Bauer NA., Koch MD., Eliason S., Jaggi M. and **Chauhan SC.** Comparative expression profile of transmembrane mucin MUC1 in breast cancer from American Indian and Caucasian women. *103 American Association of Cancer Research (AACR) Annual Meeting 2012, Chicago, IL.*
 89. Gupta BK., Maher DM., Ebeling MC., Lynch DW., Koch MD., Puumala SE., Aburatani H., Jaggi M. and **Chauhan SC.** Role of MUC13 in colon cancer progression. *103 American Association of Cancer Research (AACR) Annual Meeting 2012, Chicago, IL.*
 90. Sundram V., **Chauhan SC.** and Jaggi M. *Curcumin Modulates Protein Kinase D1 Signaling in Prostate Cancer.* Fourth International Conference on Translational Cancer Research. Rajasthan, India. *December 17, 2011.*
 91. Gupta BK., Jaggi M. and **Chauhan SC.** Clinio-pathological significance of MUC13 mucin in colon cancer. Fourth International Conference on Translational Cancer Research. Rajasthan, India. *December 17, 2011.*
 92. Nordquist J., Maher DM., Ebeling M., Jaggi M. and **Chauhan SC.** Ormeloxifene treatment inhibits growth of cisplatin-resistant ovarian cancer cells. *102 AACR Annual Meeting 2011, Orlando, FL*
 93. Gupta BK., Maher DM., Verma R., Ebeling M., Lynch D., Koch M., Watanabe A., Aburatani H., Jaggi M. and **Chauhan SC.** MUC13 expression enhances colon cancer progression. *102 AACR Annual Meeting 2011, Orlando, FL*
 94. Yallapu MM., Othman SF., Curtis ET., Gupta BK., Jaggi M. and **Chauhan SC.** Multifunctional magnetic nanoparticles for theranostic applications. *102 AACR Annual Meeting 2011, Orlando, FL*
 95. Hughes JE., Radel S., Sundram V., Jepperson TN., Koch MRD., **Chauhan SC.** and Jaggi M. Protein Kinase D1 expression attenuates colon cancer progression. *102 AACR Annual Meeting 2011, Orlando, FL*
 96. Yallapu MM., Ebeling M., Maher DM., Jaggi M. and **Chauhan SC.** Targeted curcumin delivery approach for improved prostate cancer therapeutics. *DOD IMPACT Meeting 2011, Orlando, FL*
 97. Jaggi M., Sundram V., Radel S. and **Chauhan SC.** Protein Kinase D1 suppresses B-catenin/T cell factor activity and attenuates prostate cancer growth. *DOD IMPACT Meeting 2011, Orlando, FL*
 98. Dobberpuhl M., Yallapu MM., Maher DM., Gupta BK., Jaggi M. and **Chauhan SC** Enhancing the efficacy of curcumin for prostate cancer treatment using cellulose nanoparticles. *8th International Nanomedicine and drug delivery systems-Omaha NanoDDS10, Oct 3-5, Omaha, NE*
 99. **Chauhan SC.** A novel strategy for sensitizing cancer cells. *21st Annual Antibody Engineering Conference, San Diego, December 5-9, 2010*

100. Yallapu MM, Othman SF., Curtis ET., Gupta BK., Jaggi M, and Chauhan SC. Multi-functional Magnetic Nanoparticles for magnetic Resonance Imaging and Cancer Therapy. 8th International Nanomedicine and drug delivery systems-Omaha NanoDDS10, Oct 3-5, Hilton Omaha, Omaha, NE
101. **Chauhan SC.**, Ebeling MC., Maher DM., Koch MRD., Friez MH., Watanabe A., Aburatani Hiroyuki., Lio Y., Pandey KK and Jaggi M. MUC13 mucin augments pancreatic tumorigenesis. *101 AACR Annual Meeting 2010*, Washington DC
102. Nordquist J., Jaggi M and **Chauhan SC.** Effects of drug X on cisplatin-resistant and cisplatin-sensitive ovarian cancer cells. **21st Annual Meeting of the European Association for Cancer Research (EACR) 2010.** Oslo, Norway, June 26-29.
103. Maher D., Yallapu MM., Sundram V., Bell MC., Jaggi M., **Chauhan SC.** Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. *101 AACR Annual Meeting 2010*, Washington DC.
104. Prakash Preethi., Friez MH., Bohlmeier T., Koch MRD., **Chauhan SC.**, Jaggi M. Downregulation of Protein Kinase D1 in hepatocellular carcinoma (HCC): Potential as a diagnostic/prognostic molecular marker. *101 AACR Annual Meeting 2010*, Washington DC.
105. Yallapu MM., Jaggi M., **Chauhan SC.** Design of β -cyclodextrin-curcumin self-assembly: A new approach for enhanced curcumin delivery and therapeutic efficacy in prostate cancer cells. *101 AACR Annual Meeting 2010*, Washington DC.
106. Sundram V., Chauhan SC. and Jaggi M. Curcumin suppresses prostate cancer cells through modulation of β -catenin and protein kinase D1. *101 AACR Annual Meeting 2010*, Washington DC.
107. Jepperson . N, Tyler., Hughes J., Hausser A., **Chauhan SC.** and Jaggi M. Protein Kinase D1 reduces cellular proliferation and invasiveness via suppression of β -catenin/T-cell factor activity in SW480 colon cancer cells. AACR Centennial Meeting 2009, Denver, CO.
108. Ebeling MC., Jaggi M. and **Chauhan SC.** Role of MUC13 mucin in pancreatic cancer diagnosis and pathogenesis. 3rd International Symposium on Translational Cancer Research December 18-21, 2009, Bhubaneswar, Orissa, India.
109. Hughes JE., **Chauhan SC.**, and **Jaggi M.** Protein kinase D1 attenuates tumorigenesis in SW 480 colon cancer cells by modulation β -catenin/T cell factor activity. 3rd International Symposium on Translational Cancer Research December 18-21, 2009, Bhubaneswar, Orissa, India.
110. **Chauhan SC.** and Jaggi M. Role of MUC13 mucin in cancer diagnosis and cancer progression. 1st annual conference of Society for Professional Biotechnologists, December 1 through 2, 2009, Kanpur, India
111. Ebeling MC, Jaggi M and **Chauhan SC.** Role of MUC13 mucin in pancreatic cancer diagnosis and pathogenesis. 3rd International meeting Symposium on Translational Research: Cancer Cell Signaling and Therapy, December 18 through 21, 2009 in Bhubneswar (Orissa), India.
112. Hughes JE, **Chauhan SC.** and Jaggi M. Protein kinase D1 attenuates tumorigenesis in SW 480 colon cancer cells by modulation β -catenin/T cell factor activity. 3rd International meeting Symposium on Translational Research: Cancer Cell Signaling and Therapy, December 18 through 21, 2009 in Bhubneswar (Orissa), India.
113. Prakash. P., Friez. M., Bohlmeier, T., **Chauhan SC.** and Jaggi M. Differential expression of protein kinase D1 (PKD1) in various cancers and overexpression in thyroid cancer. AACR Centennial Meeting 2009, Denver, CO.
114. Maher DM., Bell MC., O'Donnell EA., Jaggi M, **Chauhan SC.** Curcumin inhibits the growth of cervical cancer cells and suppresses HPV oncoproteins E6 and E7. AACR Centennial Meeting 2009, Denver, CO.

115. **Chauhan SC.**, Ebeling MC., Bell MC., Koch MD., Watanabe A., Aburatani H., Lio Y, Pandey KK., Jaggi M. Functional aspects of a membrane anchored mucin MUC13 in ovarian cancer. AACR Centennial Meeting 2009, Denver, CO.
116. **Chauhan SC**, Stangl CM., Christianson AB., Shearer GC., Harris WS. and Jaggi M Long Chain Omega-3-Fatty Acids (n-3 FA) Suppress Colon Cancer Cells Proliferation via Inhibition of β -catenin Transcription Activity . **AACR Annual Meeting 2008**, San Diego, CA
117. **Chauhan SC.**, Yang J., Vinayek N., Koch MD., Harmon M., Bohlmeyer T., Jaggi M. and Perryman MB. Deregulated expression of myotonic dystrophy protein kinase (DMPK) in cervical cancer. **AACR Centennial Meeting 2007**, Washington DC.
118. Friez MH., Maher D., Vinayek N., Jaggi M., Vannatta K., Watanabe A., Aburantani H., Koch RD., and **Chauhan SC**. Overexpression of transmembrane mucin MUC13 in pancreatic ductal adenocarcinoma. **Pathology of the 21st Century Integrating Diagnostic and Molecular Pathology May 11-12, 2007, Houston Texas, USA**
119. Maher D., Bell MC., Jaggi M, and **Chauhan SC**. Natural Products for cervical cancer prevention and treatment. **2nd International Meeting on Translational Cancer Research and Natural Products 2007, Lonawala, India.**
120. **Jaggi M. and Chauhan SC**. Bryostatatin suppresses β -catenin transcription activity by PKD1 activation in prostate cancer cells **2nd International Meeting on Translational Cancer Research and Natural Products, 11-14 December, 2007, Lonawala, India.**
121. **Chauhan SC** and Jaggi M. Cell signaling through mucins in cancer. *Proceedings of South Dakota Academy of Science (PSDAS) 2007, Volume 86*
122. Vannatta K., Vinayek N, Watanabe A, Dunham K, Bell MC, Koch MD, Aburatani H., Jaggi M. and **Chauhan SC**. MUC13 expression and its *in vitro* functions in ovarian cancer. *Proceedings of South Dakota Academy of Science (PSDAS) 2007, Volume 86*
123. Maher D., Bell M., Wattier K., Vannatta K., Jaggi M., Srivastava S. and **Chauhan SC**. Inhibition of cervical cancer cell proliferation with chemopreventive agents and modulation of E-cadherin expression by I3C in cervical intraepithelial neoplasia **AACR Centennial Meeting 2007**, Washington DC.
124. Hughes J., Dunham K., Vinayek N., Cheng D., Balaji KC., Hausser A., **Chauhan SC**. and Jaggi M. Modulation of β -catenin/T cell by protein kinase D1 in SW 480 colon cancer cells. **AACR Centennial Meeting 2007, Washington DC.**
125. Vinayek N., Dunham K., Wattier K., Koch MD., **Chauhan SC**. and Jaggi M. Differential expression of cadherins and catenins in gynecological cancers. **AACR Centennial Meeting 2007**, Washington DC.
126. Vinayek N., Vannatta K., Watanabe A., Dunham K., Bell M C., Koch MD., Aburatan H., Jaggi M. and **Chauhan SC**. Aberrant expression of a transmembrane mucin MUC13 in ovarian cancer. 7th Joint Conference of the AACR- Japanese Cancer Association: *In the Forefront of Basic and Translational Cancer Research*, 2007 January 21-25, Waikola, Hawaii.
127. Dunham K., Vinayek N., Hughes J., Balaji KC., **Chauhan SC**. and Jaggi M. Effect of Protein Kinase D1 on β -catenin transcription activity and cell cycle in prostate cancer cells. 7th Joint Conference of the AACR- Japanese Cancer Association: *In the Forefront of Basic and Translational Cancer Research*, 2007 January 21-25, Waikola, Hawaii.
128. **Chauhan SC.**, Vinayek N., Dunham K., Lio Y., Koch MD. and Jaggi M. Analysis for MUC1, MUC16 and TAG-72 expression in ovarian cancer: Antigens of multi-targeted antibody guided therapy. **2006 AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development**, September 12-15, Chicago, IL

129. Bell MC., Schmidt-Grimminger D., Patrick S., Ryschon T., Linz L. Beck L. and **Chauhan SC.** Prevalence of Human Papillomavirus (HPV) Infection in American Indian Women in Northern Plains. *Frontiers in Women's Health: Pioneering Researchers in South Dakota*, May 15, 2006.
130. Radel S., Bell MC., Vannatta K. and **Chauhan SC.** Human Papillomavirus 59 infection induces cellular differentiation in primary human keratinocytes. *SD Biomedical Research Infrastructure Network Symposium*, August 1, 2006.
131. Wattier K., Bell MC. and **Chauhan SC.** Chemoprevention in cervical cancer. *SD Biomedical Research Infrastructure Network Symposium*, August 1, 2006.
132. Dunham K., Koch MD., **Chauhan SC.** and **Jaggi M.** Aberrant expression of E-cadherin and β -catenin in gynecological cancers. *Frontiers in Women's Health: Pioneering Researchers in South Dakota*, May 15, 2006.
133. Bell MC., Schmidt-Grimminger D., Patrick S., Ryschon T., Linz L. and **Chauhan SC.** Analysis on Human Papillomavirus (HPV) Infection in Women in Northern Plains American Indian Reservation. *97th Annual AACR Meeting, Washington DC* (2006)
134. Jain M., **Chauhan SC.**, Singh AP. and Batra SK. Improved tumor retention of divalent single chain antibody fragment by co-administration of a cell penetrating peptide penetratin. *96th Annual AACR Meeting, Anaheim, CA* (2005)
135. **Chauhan SC.**, Jain M., Baranowska-Kortylewicz J. and Batra SK. Pharmacokinetics and biodistribution of ^{177}Lu -labeled multivalent single chain constructs of the pancreatic carcinoma monoclonal antibody CC49. *94th Annual AACR Meeting, Washington DC* (2003)
136. Singh AP., Moniaux N., **Chauhan SC.**, Pandey KK, Andrianifahanana M., Jain M., Hollingsworth MA., and Batra SK, 2003. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. *11th SPORE Investigators' Workshop, Baltimore, Maryland* (July 8-10, 2003), p68.
137. Singh AP., Andrianifahanana, M., **Chauhan, SC.**, Pandey, KK., Moniaux, N., Hollingsworth, MA. and Batra SK. (2002). MUC4 mucin overexpression is associated with the cystic fibrosis phenotype. *Sixteenth Annual North American Cystic Fibrosis Conference, New Orleans, Louisiana* (October 3-6, 2002). *Pediatr. Pulmon.* (suppl 24). p200.
138. Bansode FW., **Chauhan SC.**, Makker A and Singh MM. Uterine luminal epithelial alkaline phosphatase activity and pinopod development in relation to endometrial sensitivity in rat. *International Conference on Reproductive Health, Mumbai*, 15-19 Mar 1998, pp 352-353.
139. **Chauhan SC.**, Makker A. and Singh MM. Endometrial protein profile in relation to period of maximal endometrial sensitivity in rat. *International Conference on Reproductive Health, Mumbai*, 15-19 Mar 1998, p 350.
140. Singh MM., **Chauhan SC.**, Trivedi RN., Makker A., Arshad M. and Kamboj VP. Characterization of endometrial sensitivity: A potential target for contraception. *International Conference on Reproductive Health, Mumbai*, 15-19 Mar 1998, p 351.
141. **Chauhan SC.**, Singh MM., Maitra SC., Chandra R. and Kamboj VP. Cytological changes in the uterus during high endometrial sensitivity in rat. *Proceedings of ICMR Young Scientists Symposium Frontiers in Reproductive Biology Research, Shimla*, October 8-11, 1996.
142. Trivedi RN., Singh MM., **Chauhan SC.**, Srivastava VML., Makker A. and KambojVP. Activities of certain antioxidant enzymes and dehydrogenases and histoarchitecture in relation to time of secretion of nidatory estrogen and high endometrial sensitivity in rat. *Proceedings of ICMR Young Scientists Symposium Frontiers in Reproductive Biology Research, Shimla*, 1996.
143. Makker A., Singh MM., **Chauhan SC.** & Kamboj VP. Biochemical and surface ultrastructural changes in the guinea pig uterus during high endometrial sensitivity and induced decidualization.

Proceedings of VII Annual Meeting of Indian Society of Study on Reproduction and Fertility, New Delhi, Dec 2-5, 1995.

144. **Chauhan SC.**, Singh MM., Maitra SC., Trivedi RN. & Kamboj VP. Correlation between hormonal events and endometrial sensitivity with development of pinopods on rat uterine luminal epithelium. *Proceedings of ICMR Young Scientists Symposium Frontiers in Reproductive Biology Research, Bombay*, Feb10-11, p 17, 1995.
145. Singh MM., **Chauhan SC.**, Maitra SC., Trivedi RN. and Kamboj VP. Uterine surface ultrastructure during high endometrial sensitivity in rats. *Proceedings of the Symposium on Cell Signaling and Ovo-Implantation, New Delhi*, 1994.
146. Singh MM., Makker A., **Chauhan SC.**, Dwivedi A. and Kamboj VP. Uterine estradiol and progesterone receptor concentration during high endometrial sensitivity in guinea pig. *Proceedings of the Conference on Steroid Receptors and Antihormones, USA*, Sept 20-23, abstr, 1994.
147. Singh MM., **Chauhan SC.**, Maitra SC. and Kamboj VP. Effect of estrogen and progesterone antagonists on mitochondria in uterine glandular epithelial cells in rat. *Proceedings of the Conference on Steroid Receptors and Antihormones, USA*, Sept 20-23, 1994.
148. Singh MM., Maitra SC., **Chauhan SC.**, Trivedi RN. and Kamboj VP. Displacement in appearance of pinopods on endometrial surface, but not Endometrial sensitivity, by the antiestrogen centchroman. *Proceedings of the Conference on Steroid Receptors and Antihormones, USA*, Sept 20-23, 1994.
149. Singh MM., **Chauhan SC.**, Maitra SC., Trivedi RN. and Kamboj VP. Uterine surface ultrastructure during endometrial sensitivity in rat. *Proceedings of National Symposium on Reproductive Health Care & 5th Annual Meeting of Indian Society Study of Reproduction and Fertility, Jaipur*, Feb 4-6, 1994.
150. **Chauhan SC.**, Singh MM., Maitra SC. and Kamboj VP. Displacement of the time of appearance of pinopods on rat endometrial surface by an antiestrogen. *Proceedings of National Symposium on Reproductive Health Care & 5th Annual Meeting of Indian Society Study of Reproduction and Fertility, Jaipur*, Feb 4-6, 1994.

Radio Interview:

Subhash Chauhan

South Dakota Public Broadcasting

Title: Cervical Cancer in American Indian Women

Date: 08-24-2012

TV Interview:

Subhash Chauhan

Keloland TV, Sioux Falls. South Dakota

Title: Sanford Research 2012 progress and future prospects

Date: 12-24-2012

<http://www.keloland.com/videoarchive/index.cfm?VideoFile=121223insidekeloland>

News Interview

Subhash Chauhan

Published in Indian Country Today Media Network

Title: Sanford Health Researching Cervical Cancer in Native American Women

<http://indiancountrytodaymedianetwork.com/2012/09/12/sanford-health-researching-cervical-cancer-in-native-american-women-132928#ixzz26I1tyiGx>

Date: 09-12-2012

PATENT APPLICATIONS AND AWARDS:

1. Applied for **four** US Provisional Patents for developing a novel anti-cancer drug and one patent is already approved (PCT/US2011/063723).
2. One product is pending for technology transfer to Advance Orthomolecular Research (a Canada based company)

CONSULTATION ACTIVITIES:

Grant Review Panel:

1. Texas Center for Health Disparities Univ. of North Texas Health Science Center
2. Manitoba Health Research Council, Winnipeg, Manitoba, Canada
3. U.S. Civilian Research and Development Foundation (Cooperative Grants Program)
4. Grant Reviewer NIH (Challenge Grant Panel #10 (ZRG1) 2009
5. Ad hoc member gene and drug delivery (GDD) NIH study section 2010
6. Grant Reviewer NIH Topics in Biomedical Engineering [BST-M (02)]
7. 2011 Ad hoc member gene and drug delivery (GDD) NIH study section 2011
8. Grant reviewer NIMHD Science Education Initiative Special Emphasis Panel 2011
9. Grant reviewer NIMHD RO1 grants review Special Emphasis Panel 2011
10. Grant reviewer NIMHD P20 grants review Special Emphasis Panel 2011

11. Grant reviewer NIMHD R13 grants review Special Emphasis Panel 2011
12. DOD BCRP Idea Development Grant Review panel 2011
13. Grant reviewer NIMHD P60 grants review Special Emphasis Panel 2012
14. Grant reviewer NIMHD 24 grants review Special Emphasis Panel 2012
15. Grant reviewer NIMHD R13 grants review Special Emphasis Panel 2012
16. 2012 Ad hoc member gene and drug delivery (GDD) NIH study section 2012
17. November 2012 ZRG1 OBT-Z (55) R PAR Panel: Cancer Health Disparities/Diversity in Basic Cancer Research
18. March 2013 ZRG1 OBT-Z (55) R PAR Panel: Cancer Health Disparities/Diversity in Basic Cancer Research
19. November 2013 ZRG1 OBT-Z (55) R PAR Panel: Cancer Health Disparities/Diversity in Basic Cancer Research
20. April 2014 ZRG1 OBT-Z (55) R PAR Panel: Cancer Health Disparities/Diversity in Basic Cancer Research
- 21. Permanent member gene and drug delivery (GDD) NIH study section 2013-2017***
22. DOD 2013 Peer Reviewed Medical Research Program, Pre-application-Nanomedicine for Drug Delivery Science-2, PRE-NDDS-2
23. DOD 2013 Peer Reviewed Medical Research Program, Pre-IBS Panel
24. 2013 Texas Center for Health Disparities Univ. of North Texas Health Science Center
25. 2014 Texas Center for Health Disparities Univ. of North Texas Health Science Center
26. 2014 Swiss Cancer League review panel
27. 2014 West Cancer Intramural Grant review panel
28. 2014 KY Lung Cancer Research Program Grant review panel
29. 2015 Danish Council for Independent Research grant review panel
30. 2015 National Research Mentoring Network (NRMN) grant review panel.
31. UTHSC, College of Pharmacy seed grant review panel
32. Served on a NIH special emphasis panel ZMD1 XLN (2) (09/2015)
33. Served as reviewer NIA AACP review panel
34. Served as NCI Reviewer: NCI Small Grants Program for Cancer Research and NCI Exploratory/Development Research Grant Program (Ominbus R03 and R21) ZCA1 TCRB-6 M1

Research Interest: Developing Molecular Markers for Early Cancer Diagnosis and Targeted Therapy for Cancer Treatment

Biomarkers for Early Cancer Diagnosis: Primary research interest of Dr. Chauhan's lab is to identify and characterize the diagnostic and therapeutic targets for cancer. Main focus of our research group is to elucidate the regulatory mechanisms of cell-cell adhesion and anti-adhesion molecules that cause cancers. This research is aimed for the identification and characterization of biomarkers that aberrantly express or localize in cancer cells in order to develop newer tools for early disease diagnosis. We are utilizing genomics and proteomics approach for identification of novel early diagnostic markers. Recently we have identified a novel trans-membrane mucin MUC13 which is highly over-expressed ovarian and pancreatic and colon cancer cells. This may be potential biomarker for early cancer diagnosis as well as a good target for antibody guided targeted cancer therapy.

Optimization of Radioimmunotherapy for Cancer Treatment: The other research interest of Dr. Chauhan's lab is to develop novel radioimmunotherapy (RIT) and radioimmunodiagnostic (RID) modalities for the treatment and diagnosis of gynecological malignancies. Monoclonal antibodies/engineered single-chain Fvs offer a powerful approach to cancer therapy in view of their exquisite specificity and targeting capability via the delivery of cytotoxic agents (i.e. radionuclides, enzymes, genes, drugs and cytotoxins). This research project is aimed to develop novel genetically engineered antibody molecules with reduced immunogenicity, desirable size and altered pharmacokinetics for the RID/RIT applications.

Development of a Novel Nanotechnology Based Therapy: Nonspecific distribution and suboptimal delivery of the anti-cancer drug(s) to the tumor cells are the major hindrances in the successful use of traditional chemotherapy. The cancer tissues overexpress TAG-72, MUC1, MUC13 and MUC16 antigens, and a combination of the antibodies against these three antigens will potentially recognize 100% of the cancer cells. These antibodies can be used to deliver the *radionuclides and nanoparticles-encapsulated drugs* specifically to the cancer cells. In addition, antibodies that have been labeled with alpha and beta emitting radionuclides (²¹¹At, ¹⁷⁷Lu and ¹³¹I) of different linear energy transfer (LET) and have been designed against these tumor antigens will effectively target various sizes of metastatic lesions. Additionally, we are also developing a novel nanotechnology based gene therapy for cancer.

Information for the Lay Person:

Primary research interest of Dr. Chauhan's lab is to identify and characterize the diagnostic and therapeutic targets for cancer, such as ovarian cancer, cervical cancer, prostate cancer, pancreatic cancer. This research is aimed for the identification and characterization of biomarkers that aberrantly express or localize in cancer cells in order to develop newer tools for early disease diagnosis. Recently we have identified a novel trans-membrane mucin MUC13 which is highly over-expressed ovarian and pancreatic cancer cells. This may be potential biomarker for early cancer diagnosis as well as a good target for antibody guided targeted cancer therapy.

Press Releases:

Curcumin nanoparticles the key to resistant cancers

Pre-treatment with curcumin, a component of the spice turmeric, makes ovarian cancer cells more vulnerable to chemo- and radio-therapy. Researchers writing in BioMed Central's open access *Journal of Ovarian Research* found that delivering the curcumin via very small (less than 100nm) nanoparticles enhanced the sensitizing effect.

Subhash Chauhan, PhD and Meena Jaggi, PhD led a team of researchers from the Sanford Research/USD and University of South Dakota, USA, carried out the in vitro study. They said, "One

strategy to improve the effectiveness and limit the toxicity of cancer therapy is to induce chemo/radio-sensitization in cancer cells using natural dietary phytochemicals like curcumin. However, curcumin is poorly absorbed by the body, which limits its effectiveness; therefore, we have developed a nanoparticle formulation, Nano-CUR, to provide increased bioavailability as well as targeted delivery of curcumin into tumors”.

The researchers tested the effects of their curcumin formulation on therapy-resistant ovarian cancer cells. They were able to show, for the first time, that the pre-treatment lowers the dose of cisplatin and radiation treatment needed to suppress the growth of the cancer cells. According to Chauhan, “Nanoparticle mediated curcumin delivery will further improve the sensitization and therapeutic capabilities. This study demonstrates a novel pre-treatment strategy that could be implemented in pre-clinical animal models and in future clinical trials”.